Novartis AG Investor Relations

Q2 2020 Results Investor Presentation July 21, 2020 Disclaimer

This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding our estimates of the impact of past and future COVID-19 related forward purchasing on sales and on our performance; or regarding the impact of the COVID-19 pandemic on clinical trials, and research and development timelines; or regarding potential future, pending or announced transactions; regarding potential future sales or earnings of the Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions; or regarding the Group’s liquidity or cash flow positions and its ability to meet its ongoing financial obligations and operational needs; or regarding efforts to provide a not-for-profit portfolio of medicines for symptomatic treatment of COVID-19. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: liquidity or cash flow disruptions affecting our ability to meet our ongoing financial obligations and to support our ongoing business activities; the impact of the COVID-19 pandemic on enrollment in, initiation and completion of our clinical trials in the future, and research and development timelines; the impact of a partial or complete failure of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in the second half of 2020; global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the transactions described, may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of potentially transformational technologies and business models; uncertainties regarding actual or potential legal proceedings, investigations or disputes; our performance on environmental, social and governance measures; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Enbrel® is a registered trademark of Amgen, Inc. Humira® and Skyrizi™ are registered trademarks of Abbvie Inc. Siliq® is a registered trademark Valeant Pharmaceuticals International, Inc. Taltz® is a registered trademark of Eli Lilly and Company. Stelara®, Tremfya® and Simponi® are registered trademarks of Janssen Biotech, Inc. Cimzia® is a registered trademark of UCB Group of Companies.

2 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Participants

Vas Narasimhan John Tsai Chief Executive Officer Head of Global Drug Development and CMO

Harry Kirsch Richard Saynor Chief Financial Officer CEO, Sandoz

Marie-France Tschudin Shannon Thyme Klinger President, Novartis Pharmaceuticals Chief Legal Officer

Susanne Schaffert President, Novartis Oncology

3 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Company overview

4 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Strong H1 performance despite the impact of COVID-19 H1 results more representative of performance as Q1 forward purchasing largely reversed in Q2

Strong operational performance Delivering on innovation Robust pandemic response Continuing operations1, % cc vs. PY Human capital US approval NSCLC Health and safety of associates, patients, third Net sales Core OpInc parties2 US/EU approval nr-axSpA, Q2 2020 China AS, CHMP PedPsO Supply chain Operations remain stable with customer service H1 2020 levels at a record high 19% EU conditional approval SMA IV Clinical trials Disruptions managed with SENSE and Site Cockpit EU approval asthma digital technologies 6% 6% +ve CHMP opinion HR+/HER2- Collaborations & drug discovery aBC Ph3 clinical trials with canakinumab and ruxolitinib3, 35+ investigator-initiated trials Label update in US COVID-19 Access portfolio (15 medicines offered to 79 LICs, LMICs)4 +ve CHMP opinion CRSwNP

-1% 5 simultaneous approvals in Japan For footnotes see slide 49

5 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Growth drivers continuing strong momentum

Key growth driver sales H1 2020 Key growth drivers and launches, Sales Growth vs. PY Growth vs. PY as % of Innovative Medicines sales USD Million USD Million cc 1,149 50% 212 159 371 47% Adakveo® 375 170 190 360 nm Mayzent® Beovu® 1,874 139 86 15% 225 ® 37% Piqray 825 96 73 169 28% Xiidra®

® 169 90 79 169 nm Lutathera 30% Kymriah® 153 74 73 nm 147 Kisqali® 320 70 48 118 64% 24% Zolgensma® Ilaris® 211 48 60 108 106% Jakavi® 102 68 34 102 nm Tafinlar+Mekinist® 737 69 31 100 19% Promacta® Entresto® 413 62 35 97 33% Cosentyx® 628 60 26 86 20% Other1 H1 2017 H1 2018 H1 2019 H1 2020

nm – not meaningful Q1 20 Q2 20 1. Includes Tasigna®, Xolair®, Aimovig® and Luxturna®

6 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Zolgensma® (USD 205m): Growth driven by geographic expansion

Q2 highlights Regulatory and other milestones

USD 205m Strong global momentum despite COVID-19 AVXS-101 IT Continued dialogue with FDA partial clinical Planning pre-BLA meeting Submission expected 2021 60% newborns screened by end Q2, Medicaid access hold 86% of lives covered, permanent J-code in place Some COVID-related disruption normalizing Geographical Approvals expected H2 2020 / early Received conditional approval with broad label1 expansions 2021: Switzerland (Fast Track), Day One access program Canada (Priority Review), Israel, Germany: agreements with 90% of sick funds Australia, Argentina, South Korea, Early access in other countries Brazil

Fast uptake in 1st month of launch Manufacturing Continued progress with Colorado expansion and North Carolina sites expected Others Requests continue in pre-approved markets operational 2021 (e.g. Middle East, Russia)

1. Patients with SMA and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene. The approval covers babies and young children with SMA up to 21 kg according to the approved dosing guidance

7 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Sandoz H1 results highlight continuing good performance, despite negative Q2 impact of COVID-19

Net sales Core OpInc % cc vs. PY H1 results more representative of performance as Q1 forward purchasing largely reversed in Q2 Q2 2020 H1 2020 26% H1 performance drivers . 25% sales growth Biopharmaceuticals . +3% Retail ex-US . Rapid Aspen Japan integration 1% 1% . Continuous gross margin and core ROS improvement Other dynamics . COVID-19 negatively impacted hospital / pharmacy traffic lowering demand . US oral solids and dermatology decline and partnership terminations

-9%

8 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation In-market growth drivers, major launches and a rich pipeline expected to sustain our long-term growth

. 15 ongoing / upcoming major launches . 80+ major submissions planned to 2022 New indications . 50+ late stage programs1 Cosentyx® HS Alpelisib PROS Novel assets Cosentyx® GCA Piqray® TNBC Cosentyx® LP Piqray® HER2+ aBC Ofatumumab MBG453 Cosentyx® JIA Piqray® ovarian cancer Inclisiran Asciminib Major launches Cosentyx® LN Piqray® HNSCC TQJ230 Canakinumab Entresto® post-AMI Kisqali® HR+/HER2- BC (adj) LNP023 Spartalizumab In-market Entresto® HFpEF Kymriah® FL Iscalimab 177Lu-PSMA-617 growth drivers Beovu® DME Kymriah® DLBCL Ligelizumab Beovu® RVO Jakavi® cGVHD LNA043 Beovu® DR Jakavi® aGVHD Tropifexor Beovu® PDR UNR844 Ofatumumab pediatric CEE321 AVXS-101 IT LOU064 Xolair® food allergy VAY736 LMI070 QBW251 SELECT EXAMPLES 1. Ph3 / in registration

9 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Advancing our late stage pipeline Selected assets

Asset Indication Current status Next milestone

Ofatumumab (OMB157) RMS In registration FDA action date September 2020 Inclisiran (KJX839) Hyperlipidemia US / EU submissions complete; review on track FDA action date December 2020

Alpelisib (BYL719) PROS Real World Evidence (RWE) Ph2 ongoing US submission expected H2 2020 2020 Tafinlar®+Mekinist® mBRAF V600 + Ph3 readout on track 2020 Submission on track by end of 2020 w/ spartalizumab melanoma Asciminib (ABL001) CML Pivotal study in 3L On track for readout 2020; first submission expected Q1 2021 Canakinumab (ACZ885) NSCLC Enrollment complete in 1L (CANOPY-1) and DMC IA data readout (CANOPY-1) expected Q4 2020; 2L (CANOPY-2) studies CANOPY-1 and CANOPY-2 readouts & filings expected 2021 177Lu-PSMA-617 mCRPC VISION Ph3 trial: slower than expected event accumulation Event driven trial; readout expected H1 2021 rate; preparations ongoing for starting earlier line studies Entresto® HFpEF, post-AMI HFpEF filed FDA action expected by H1 2021

PARADISE-MI enrollment complete PARADISE-MI study results expected 2021 2021 AVXS-101 IT SMA IT Partial clinical hold: continued dialogue with FDA Planning pre-BLA meeting; submission expected 2021 Ligelizumab (QGE031) CSU PEARL 1 and 2, superiority studies vs. Xolair® (Ph3) Ph3 enrollment on track to complete 2020; ongoing readout and submission expected H2 2021 Kisqali® Adjuvant BC NATALEE study on track, enrollment ongoing MONALEESA-2 OS readout expected 2021 NATALEE Ph3 aBC readout expected 2022

10 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Emerging pipeline assets continue to progress Selected assets

Asset MoA Indication Current status Next milestone LNP023 Factor B PNH, IgAN, C3G, Ph2 parallel development for 3 rare renal diseases and Single PNH pivotal trial expected to start 2020; inhibitor iMN, aHUS paroxysmal nocturnal haemoglobinuria (PNH) C3 glomerulopathy, IgA nephropathy

Ph3 expected to start Q1 2021 Pharmaceuticals

Remibrutinib Bruton tyrosine kinase CSU, Sjögren’s Ph2b study in CSU and adaptive Ph2 in Sjögren’s ongoing Phase 2b study in CSU expected to readout (LOU064) inhibitor 2021

Iscalimab Anti-CD40 monoclonal Kidney Tx, Sjögren’s Ph2b studies in kidney transplant, Sjögren’s ongoing Anticipated regulatory submission for (CFZ533) antibody kidney transplant 2023

TQJ230 Antisense CVRR-Lp(a) Ph3 outcomes study (HORIZON) initiated 2020 Ph3 outcomes readout expected 2024 oligonucleotide targeting LP(a)

MBG453 Anti-TIM-3 monoclonal HR-MDS, Ph3 study in HR-MDS initiated Jun 2020 (STIMULUS- Ph2 in unfit AML (combo HMA + venetoclax)

antibody unfit AML MDS-2) expected to start 2020 Oncology LXH254 B/C-RAF inhibitor m RAS/RAF NSCLC Clinical studies ongoing, evaluating LXH254 in combination Ph2 metastatic melanoma trial and melanoma with LTT462 (ERKi), Mekinist®, Kisqali® and spartalizumab expected to start 2020

TNO155 SHP2 inhibitor Solid tumors Broad combination strategy with multiple Ph1 combo Continued enrollment in all 3 trials, studies ongoing including spartalizumab, Kisqali®, including recently started trial with nazartinib, MRTX849 MRTX8491

1. Study sponsored by Mirati Therapeutics

11 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Progressing on our journey of building trust with society

Ethical Established robust governance Continuously evolving Resolved long-standing standards legacy legal matters Tone from the top (zero tolerance) Trust & Reputation Pricing Committee chaired by CEO Speaker programs settlement Ethics Risk Compliance (ERC) Officer (2002-2011) & access member of Executive Committee Launching Code of Ethics, elevating principles-based Independent charitable co-pay Global Link ethics to performance policy foundations settlement management (including sales force and health (2010-2014) executives) Enterprise risk management approach, third party risk Sandoz resolves US generic drug Corporate Continued use of data analytics to assessments, human rights antitrust criminal investigation citizenship generate compliance insights (2013-2015) Evolving peer-to-peer >200 country monitoring visits annually, medical education towards FCPA investigations now closed 500 ERC associates globally digital (incl. new CIA) (2007-2015)

12 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Financial review and 2020 guidance

13 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Strong H1 performance despite impact of COVID-19

Continuing operations1 Q2 Change vs. PY H1 Change vs. PY USD million 2020 % USD % cc2 2020 % USD % cc 2

Net Sales 11,347 -4 -1 23,630 3 6

Core Operating income 2 3,669 1 6 7,846 14 19

Operating income 2,352 -12 -4 5,096 4 11

Net Income 1,867 -11 -4 4,040 2 9

2 Core EPS (USD) 1.36 1 6 2.92 15 19

EPS (USD) 0.82 -10 -3 1.77 3 11

Free Cash Flow 2 3,631 1 5,652 3

1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 54 of the Condensed Financial Report.

14 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Continuing operations delivering core margin expansion of 3.8%pts cc vs. PY

Continuing operations1

Q2 2020 H1 2020

Core operating Core operating Net sales income Core margin Net sales income Core margin change vs. PY change vs. PY Core margin change vs. PY change vs. PY change vs. PY Core margin change vs. PY (in % cc) (in % cc) (%) (%pts cc) (in % cc) (in % cc) (%) (%pts cc)

Innovative Medicines 1 5 35.9 1.3 7 16 36.5 2.8

Sandoz -9 1 22.0 2.2 1 26 24.5 4.9

Continuing Operations -1 6 32.3 2.1 6 19 33.2 3.8

1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 54 of the Condensed Financial Report.

15 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Many therapy areas impacted by COVID-19 early in Q2, seeing rebound in June

Ophthalmology, dermatology and new patient starts are more impacted

IM Weekly Sales Evolution 4 weeks rolling, indexed to Q4 weekly sales avg. Beginning of COVID-19 lockdowns Impact of Beovu across US and Europe launch pre-ASRS Recent Launches1 125% communication Growth Drivers (excl. Cosentyx®)2 Beovu®, Lucentis® & Xiidra® 100% Cosentyx®

Q2 Cosentyx® (US data) . Recovered in June to Q4 2019 levels 75% . Increasing market share in dermatology and rheumatology

Mature Ophthalmology3 50% Feb 29 Mar 31 Apr 30 May 31 Jun 28

Note: lines represent rolling four-week sales average as compared to average weekly sales of Q4 2019 1. Recent launches include Adakveo®, Aimovig®, Kisqali®, Kymriah®, Lutathera®, Mayzent®, Piqray® and Zolgensma® 2. Growth drivers include Entresto®, Ilaris®, Jakavi®, Promacta®, Tafinlar®+Mekinist® and Xolair® 3. Includes Luxturna®

16 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Core OpInc growth in H2 expected to be impacted by increased generic erosion Key drivers of core operating income (continuing operations) vs. PY (cc) ILLUSTRATIVE

H1 2020 + Continued strong momentum in H2 2020 Innovative Medicines growth drivers + Innovative Medicines growth and launches1 uptake drivers, and launches1 + Productivity and lower spend driven + Productivity by COVID-19 related lockdowns − Increased Gx erosion2 − Gx erosion2 − Increased investments in pre- − COVID-19 related negative impact launch activities and launches on Lucentis® and mature ophtha − Lapping Xiidra® acquisition

1. Including Zolgensma®, Mayzent®, Aimovig®, Xiidra®, Piqray® 2. Including Afinitor ®, Exjade®, Sandostatin® LAR and Ophtha brands

17 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 2020 FY guidance1 tightened within prior guidance ranges

Continuing operations | barring unforeseen events; growth vs. PY in cc

Sales expected to grow mid single digit . IM Division expected to grow mid single digit . Sandoz expected to grow low single digit

Core operating income expected to grow low double digit

1. Our guidance assumes that we see a continuation of the return to normal global healthcare systems including prescription dynamics, particularly ophthalmology, in H2 2020. In addition, we assume that no Gilenya and no Sandostatin LAR generics enter in 2020 in the US

18 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation H1 2020 free cash flow increased to USD 5.7bn

Continuing operations1 free cash flow2 USD billion

+3% Key drivers vs. PY: 5.5 5.7 + Higher operating income (adjusted for non-cash items)

− Lower divestment proceeds

H1 2019 H1 2020

1. Refers to continuing operations as defined on page 42 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions 2. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 54 of the Condensed Interim Financial Report

19 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Expected currency impact for full year 2020

Currency impact vs. PY %pts, assuming mid-July exchange rates prevail in 2020

FX impact on Net sales FX impact on Core operating income

0 0 0 to -1 -2 -1 to -2 -3 -3 -3 -3 -5 -5 -4 -6 FY Q1 Q2 Q3 Q4 FY FY Q1 Q2 Q3 Q4 FY

2019 2020 2019 2020

Actual Simulation

20 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 21 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation H1 performance solid Accelerating our digital transformation

Pharmaceuticals net sales USD billion, growth in % cc H1 sales grew +8% as growth drivers continued momentum . Entresto® sales +50%, Cosentyx® sales +15% +8% . Zolgensma® sales USD 375m, Xiidra® sales USD 169m

11.2 11.7 Q2: COVID-19 had negative sales impact 0.1 0.8 . Lucentis® down -24% due to market decline 3.3 . Mature ophthalmology4 products down -32%5 4.0 . Cosentyx® up +12% despite COVID-19 impact

7.8 6.9 Accelerating digital transformation . Pivoted to hybrid F2F / virtual promotion and patient support for in-market brands and launches H1 2019 H1 2020 . Leading virtual scientific and medical engagement at congresses

Growth drivers1 Recent launches2 Mature products3

1. Cosentyx®, Entresto®, Ilaris®, Xolair® 2. Zolgensma®, Xiidra®, Aimovig®, Luxturna®, Mayzent® and Beovu® 3. All other brands 4. Includes Luxturna® 5. Includes generic impact primarily for Travatan®

22 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® grew faster than PsO and SpA market in US despite COVID-19 impact Sales evolution USD million, % cc Market growth declined due to COVID-19 . Visits declined 50%1 in EU and 80-90%2 in US at peak Ex-US Cosentyx® US growth above market3,4 due to strong safety, efficacy US +12% and broad access . Sales now showing recovery towards pre-COVID dynamics 944 858 . PsO QoQ: TRx +5% vs. market 0%, NBRx -24% vs. market -30% 330 324 . SpA QoQ: TRx +9% vs. market +2%, NBRx -16% vs. market -21% Further approvals 534 614 . Launching nr-axSpA in US / EU (1.7m potential patients) . AS approved in China Q2 2019 Q2 2020 . PedPsO positive CHMP opinion

TRx = Total Prescriptions; NBRx = New-to-Brand Prescriptions; nr-axSpA = non-radiographic Axial Spondyloarthritis; PedPsO = Pediatric Psoriasis; CHMP = Committee for Human Medicinal Products. 1. IQVIA COVID-19 Tracker, EU5 Countries - Wave 1, 19th June 2020. 2. Spherix Global Insights, "Multi-Specialty Impact of COVID-19". 3. IQVIA National Prescription Audit for Dermatology WE 06/26/2020; market includes Enbrel®, Humira®, Siliq®, Skyrizi™, Stelara®, Taltz®, Tremfya®. 4. IQVIA National Prescription Audit for Rheumatology WE 06/26/2020; SpA market includes Cimzia®, Enbrel®, Humira®, Simponi®, Stelara®, Taltz®

23 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® poised to maintain strong position in growing dermatology market, set to accelerate in rheumatology

>340k patients reached, >5 years efficacy and safety data, strong 1st-line access

Potential to expand into Ready to accelerate in multiple indications Strong dermatology position rheumatology Dermatology: PedPsO, HS, Lichen Planus, totaling >3m patients5 USD 12bn market WW, double-digit growth long-term Rheumatology: jPsA/ ERA, GCA, Lupus USD 17bn market WW, double-digit Nephritis, totaling >500k patients5 growth long-term 14% axSpA, 23% PsA biologic penetration3,4 Potential label updates: 300mg AI/PFS, 15% biologic penetration1,2 flexible PsO dosing, IV for SpA Strong joint efficacy in AS9 and PsA10 with 8/10 patients achieve clear or almost growing guideline11 support clear skin7 PREVENT reinforces substantial benefits Dedicated studies in scalp, nails, across axSpA spectrum palmoplantar8 Additional evidence generation in PsA12 Poised to remain biologic of choice for 2/3 of patients with multiple manifestations6

For footnotes see slide 49

24 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Strong Entresto® performance driven by underlying demand

Sales evolution USD million, % cc Maintains strong growth despite COVID-19 market slowdown Ex-US . Q2 sales of USD 580m, strong demand across geographies US . US weekly NBRx rebounded to >3,800 in June1 +40% 580 Strong foundation for future growth . 25% of 3.4m eligible HFrEF population received Entresto® in G72 421 272 . FDA accepted HFpEF file 200 . PARADISE post-AMI on track for readout mid-2021 308 221 . Geographical expansion with Japan approval; launch expected H2 2020

Q2 2019 Q2 2020

HFrEF – Heart failure with reduced ejection fraction HFpEF – Heart failure with preserved ejection fraction 1. US NBRx - IMS New to Brand w/e 06/19/20; 2. IQVIA NPA – TRx March ‘20

25 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Beovu® US label updated New data reinforces need for fluid control in wAMD

Characterization complete, Progressing label updates, New post-hoc data confirms lower levels of root-cause analysis ongoing continuing launches retinal fluid are associated with better BCVA1

SRC completed post hoc review of Updated labels in US, JP, CH, Adjusted mean BCVA change Wk12-96 (ETDRS letters) reported post-marketing events and AUS3, adding clarifying safety concluded similar events were present in language to warnings & H&H. SRC noted similar overall rates of precautions4 vision loss between H&H treatment arms. Beovu® now approved in 30 Launched coalition with 25 experts to countries, launches ongoing evaluate root-causes, risk factors, mitigation and treatment options Regular updates on brolucizumab.info

Beovu® benefit-risk profile remains positive Beovu® better in reducing retinal fluid (IRF/SRF)

DA = Disease Activity; H&H = Hawk & Harrier; SRC = Safety Review Committee; IRF = Intraretinal Fluid; PED = Pigment Epithelial Detachment; SRF = Subretinal fluid 1. Source: Schmidt-Erfurth et al. A comparison of the therapeutic response between brolucizumab and aflibercept in the HAWK & HARRIER trials using deep learning-based OCT analysis. ARVO Annual Meeting, May 2020 2: IRF, SRF, PED 3. Ongoing in all other countries where Beovu is approved 4. Retinal vasculitis and/or retinal vascular occlusion that may result in severe vision loss

26 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Ofatumumab has the potential to become a 1st choice for a broad range of RMS patients and physicians

Potential for broad and early high efficacy in RMS Based on strong ASCLEPIOS I & II data

Powerful sustained efficacy Superior efficacy for relapses, MRI activity Favorable safety Substantial reductions in disability progression1 Precise and targeted B-cell therapy 9/10 patients had no evidence of disease activity in year 22 Flexibility through at home self-administration No significant signals of infections/ malignancies

Launch leverages established position and deep customer insights

✓ Rapid and broad availability of ✓ Highly customized approach ✓ Flexible and customer-centric Ofatumumab upon approval for early adopters onboarding process

RMS = Relapsing Multiple Sclerosis; 1. CDW, confirmed disability worsening and CDP, confirmed disability progression are interchangeable terms, defined by an increase ≥1.5 EDSS points for patients with baseline EDSS of 0, increase of ≥1.0 EDSS points patients with baseline EDSS of 1.0-5.0 and increase of t ≥0.5 EDSS points for patients with baseline EDSS of 5.5. 2. Hauser S.L. et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials. Poster presented at EAN, 23-26 May 2020 LB62

27 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Inclisiran launch preparations are progressing – FDA action date Dec 2020

Advancing launch preparations Addressing non-clinical barriers to uptake

Access Allowing rapid patient onboarding at FDA action date Dec 2020 point of care

Review ongoing Affordability Ensuring lowest possible co-pay for majority of patients MAA submitted to Swissmedic in May Adherence Enabled by twice yearly HCP administration Clinical trial application accepted in June System costs Aligning to ASCVD objectives of NHS partnership on track systems of care

Source : US Truven Data, Safford M, et al. Am J Prev Med. 2015; 48(5): 520-527, National Center for Chronic Disease Prevention and Health Promotion , Division for Heart Disease and Stroke Prevention, American Heart Association CVD Burden Report (accessed 06/20), Wong ND, et al. J Clin Lipidol. 2016;10(5):1109–1118; 1. Adapted from: Ference BA et al. J Am Coll Cardiol. 2018; 72(10); 1141-1156-

28 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 29 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Recent launches and growth drivers more than offset generic impact in H1 2020

Oncology net sales USD billion, % cc H1 sales up +6% cc, despite significant Gx erosion +6% Strong uptake of recent launches in Q2 6.9 7.2 ® ® 0.4 . Kisqali (USD 159m, +49% cc), Kymriah (USD 118m, +103% cc) 0.5 0.9 ® ® 0.2 0.4 . Piqray (USD 79m), Adakveo (USD 21m), Tabrecta™ 0.2 . Lutathera® (USD 105m, -3% cc) impacted by COVID-19 1.8 2.2 1.1 Growth drivers continued double-digit performance in Q2 4.6 0.9 4.1 . Promacta® / Revolade® (USD 422m, +23% cc), Tafinlar® + Mekinist® (USD 371m, +12% cc), Jakavi® (USD 310m, +14% cc)

H1 2019 H1 2020

Recent launches1 Growth drivers2 Base business3

1. Recent launches include Kisqali®, Kymriah®, Lutathera®, Piqray®, Adakveo® 2.Growth drivers include Promacta®/Revolade®, Jakavi® (marketed by Novartis ex-US), Tafinlar®+ Mekinist®. 3. Base business – other brands.

30 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Kisqali®: Strong performance despite CDK4/6 market slowdown in the US

Net sales . H1 sales up +64% cc, reflecting continued share gains as the only USD m, % cc +64% CDK4/6 inhibitor with two positive OS readouts; third OS readout (MONALEESA-2) expected 2021 320 . Kisqali® has a differentiated profile vs. other CDK4/6 inhibitors, with preferential inhibition to CDK4 vs. CDK6, and a high concentration to inhibit the target +49% 202 . US overall CDK4/6 class growth has been slowing down due to 159 delays in new patient starts (NBRx down ~10% in Q2 vs. PY)1

111 . Rolled out in-home monitoring to support patients and HCPs during the pandemic

. NATALEE adjuvant study on track to complete enrollment of 4k patients in 2020 Q2 2019 Q2 2020 H1 2019 H1 2020

1. IQVIA Raw NBRx data, March 16, 2020 – May, 2020.

31 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Kymriah®: Sales more than doubled in H1, despite COVID impact on healthcare systems

Net sales USD m, % cc +106% . H1 sales up +106% cc, with strong growth in US and EU 211 . No interruption of supply during COVID-19

+103% . Over 25 countries covering at least one indication and more than 240 qualified treatment centers 118 103 . Continued to expand our global manufacturing network: Stein and Les Ulis sites approved for commercial supply 58 . FDA granted RMAT1 designation to Kymriah® for r/r follicular lymphoma; submission expected 2021

Q2 2019 Q2 2020 H1 2019 H1 2020

1. Regenerative Medicine Advanced Therapy

32 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Tabrecta™ (capmatinib): US launch off to an encouraging start; gearing up for launch in Japan

Development plan to Omni-channel launch amid maximize potential pandemic conditions High unmet medical need and Monotherapy studies: Phase 3, brain strong clinical profile Launched in US simultaneously with FDA- metastases, tumor agnostic approved METex14 CDx test Moving into combinations: 3-4% of NSCLC patients have METex14 mutations, associated with poor prognosis Strong early market response and positive . PD-L1 high expressers regardless of MET status, in combination with pembrolizumab and modest benefit from existing customer feedback: therapies . >20k visitors on patient website and >9k . METex14 skipping regardless of PD-L1 visitors on HCP website within 1 month status, in combination with spartalizumab ~53k addressable population worldwide . >1m views for first 3 nights of Tabrecta™ . MET amplified Post-EGFR, in combination ORR in 1L of ~70% and 2L of ~40% by Livestream Week on Twitter with osimertinib BIRC and 7 intracranial responses . >30 leading lung cancer institutions have Opportunity to serve an additional 40k observed in post hoc analysis (n=13) started patients on treatment patients Received Japan approval on June 29

Approved in US for treatment of metastatic NSCLC with exon 14 skipping mutation ORR = Overall Response Rate, BIRC = Blinded Independent Review Committee, METex14 = MET exon 14 skipping (METex14, PD-L1 = Programmed death-ligand 1, EGFR = epidermal growth factor receptor, CDx = companion diagnostic

33 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 34 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 2020 catalysts: Maintaining long-term momentum

Potential catalysts Selected examples Major approvals1 Ofatumumab (OMB157) Tabrecta™(capmatinib)5 Inclisiran (KJX839) Relapsing MS NSCLC Hyperlipidemia (US) Enerzair® / Atectura® Cosentyx® Asthma nr-AxSpA Major Inclisiran (KJX839) Alpelisib (BYL719) submissions2 Hyperlipidemia (EU) PROS Entresto® Spartalizumab (PDR001) combo HFpEF (US) Metastatic melanoma Major readouts3 Jakavi® Beovu® Canakinumab (Phase 3) Chronic GvHD DME 1st line NSCLC (IA) Asciminib (ABL001) Entresto® Chronic Myeloid Leukemia Post-acute MI (IA) Phase 3 starts TQJ2306 MBG453 CVRR MDS LNP023 Alpelisib (BYL719) PNH Multiple indications4

1. First approval in any market. 2. First submission in any market 3. Readouts enabling submission, label change or pivotal trial initiation 4. HER2+ aBC, TNBC, ovarian cancer, head and neck cancer 5. Received FDA Priority Review designation 6. Received FDA Fast Track designation

35 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Conclusion

. Strong H1 performance, confirming FY 2020 guidance

. Growth drivers on track to sustain performance

. Pipeline delivering, excited about mid to late stage assets

36 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Appendix Net debt increased by USD 10.6bn mainly due to The Medicines Company acquisition

(USD bn) -10.6

-15.9

-7.0 0.7 -0.1 -26.5 -9.9 5.7 Dec 31, 2019 Dividends M&A transactions1 Free Cash Flow Treasury share Others Jun 30, 2020 transactions, net

1. Mainly the acquisition of The Medicines Company for USD 9.6bn (excluding cash acquired of USD 0.1bn)

38 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 2020 expected pipeline milestones

✓ Achieved ✕ Missed H1 2020 H2 2020 Regulatory Beovu® nAMD (EU/JP) ✓ Adakveo® Sickle cell disease (EU) ® ™ decisions and Cosentyx nr-axSpA (EU/US) ✓ Tabrecta (capmatinib) NSCLC (US/JP) ✓ ® ® 3 opinions Cosentyx AS (CN) ✓ Cosentyx Pediatric psoriasis (EU) ✓ Ofatumumab (OMB157) Relapsing MS (US) H2 20202 Cosentyx® nr-axSpA (JP) HR+/HER2- aBC with PIK3CA Piqray® 3 Entresto® HFpEF (US) H1 2021 mutation (EU) ✓ Enerzair® Asthma (EU/JP) ✓4 Inclisiran (KJX839) Hyperlipidemia (US) Tafinlar® & Mekinist® Adjuvant melanoma (CN) ✓ Xolair® Nasal Polyposis (US/EU) ✓3 Xiidra® DED (EU) ✕ Zolgensma® IV SMA (EU/JP) ✓ Major Entresto® HFpEF (US) ✓ Alpelisib (BYL719) PROS (US) expected Inclisiran (KJX839) Hyperlipidemia (EU) ✓ AVXS-101 IT SMA (US) 2021 Juvenile PsA / enthesitis-related Cosentyx® submissions arthritis (US/EU) Spartalizumab (PDR001) Metastatic melanoma (US/EU) and Tafinlar® & Mekinist® 177Lu-PSMA-617 mCRPC (US) 2021 Entresto® Post-acute MI1 ✓ Asciminib (ABL001) CML 3L Major ® expected trial Tropifexor (LJN452) NASH ✓ Beovu DME readouts* UNR844 Presbyopia ✓ Jakavi® chronic GVHD Kisqali® aBC (MONALEESA-2 OS) 2021 177Lu-PSMA-617 mCRPC H1 2021

*Achieved = on-time readout of data, irrespective of trial outcome. 1. Planned study readout 2021; preplanned DMC interim analysis readout completed in March 2. FDA extended review with regulatory action now expected September 2020 3. Positive CHMP opinion received 4. EU approval July 2020, Japan approval June 2020

39 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Beovu: outcomes of the safety review committee analysis of HAWK & HARRIER data

4.4% IOI rate in H&H trials (reported as 4% in US PI) IOI 4% 4.6% IOI rate assessed by SRC in the post hoc unmasked analysis

3.3% Retinal vasculitis rate as assessed by SRC in the post-hoc unmasked 3% Vasculitis analysis of cases of interest (only 1 case reported by investigators in H&H)

2.1% Retinal vascular occlusion rate as assessed by SRC in the post-hoc 2% Occlusion unmasked analysis (RAO reported at 0.8% in H&H trials)

Vision loss due <1% probability of losing 15 letters or more due to IOI or retinal vasculitis

Spectrum of inflammatoryofevents Spectrum <1% to these AEs as assessed by the SRC in their post-hoc unmasked analysis

Difference in Overall vision loss similar across Beovu (7.4%) ~0 overall vision loss and Eylea (7.7%) arms at w96, as assessed in H&H and noted by SRC

IOI = Intraoccular Inflammation; PI = Prescribing Information; RAO = Retinal Artery Occlusion; AE = Adverse Event

40 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Our pipeline projects at a glance

Phase 1/2 Phase 3 Registration Total

ONCOLOGY 51 22 2 75

PHARMACEUTICALS 62 21 7 90

Cardiovascular, Renal, Metabolism 12 4 2 18 Immunology, Hepatology, Dermatology 26 6 2 34 Neuroscience 5 4 1 10 Ophthalmology 5 3 0 8 Respiratory 8 3 1 12 Global Health 6 1 1 8 Total 113 43 9 165

Biosimilars not included as we only disclose biosimilars that have moved into Phase 3 CRM: Cardiovascular, Renal & Metabolism. IHD: Immunology, Hepatology & Dermatology. NS: NeuroScience.

41 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis submission schedule New Medical Entities: Lead and supplementary indications

2020 2021 2022 2023 ≥2024

spartalizumab Lead 177Lu-PSMA-617 Lead LAG525 Lead 177Lu-NeoB Lead LNA043 Lead SAF312 Lead CSJ117 Lead PDR001 177Lu-PSMA-617 Solid Tumors 177Lu-NeoB Osteoarthritis COSP Asthma m BRAF V600+ melanoma (+Taf/Mek) mCRPC 3L Multiple Solid Tumors

asciminib Lead remibrutinib Lead 177Lu-PSMA-R2 Lead tropifexor Lead AVXS-201 Lead TQJ230 Lead ABL001 LOU064 177Lu-PSMA-R2 LJN452 OAV201 CVRR-Lp(a) CML 3L Chronic spontaneous urticaria Prostate cancer NASH Rett syndrome

MBG453 Lead iscalimab Lead VPM087 Lead tropifexor&cenicriviroc Lead LMI070 Lead ganaplacide Lead HR-MDS CFZ533 1st line CRC / 1st line RCC LJC242 SMA KAF156 Renal Tx NASH Malaria uncomplicated

ligelizumab Lead ECF843 Lead CEE321 Lead CPK850 Lead MIJ821 Lead cipargamin Lead QGE031 Dry eye Atopic Dermatitis RP Depression KAE609 Chronic urticaria Malaria severe LNP023 Lead ianalumab Lead UNR844 Lead QBW251 Lead LXE408 Lead PNH VAY736 Presbyopia COPD Visceral leishmaniasis

AIH LEAD INDICATIONS

canakinumab LCM canakinumab LCM capmatinib LCM spartalizumab LCM remibrutinib LCM inclisiran LCM ACZ885 ACZ885 INC280 PDR001 LOU064 KJX839 NSCLC 2L Adjuvant NSCLC Solid tumors Malignant melanoma (combo) SjS CVRR-LDLC

canakinumab LCM LNP023 LCM crizanlizumab LCM iscalimab Lead tropifexor LCM LNP023 LCM ACZ885 C3G SEG101 CFZ533 LJN452 iMN NSCLC 1L Sickle cell anaemia with crisis ped Liver Tx NASH (combos)

LNP023 LCM MBG453 LCM iscalimab LCM ofatumumab LCM cipargamin LCM IgAN Maintenance for MRD+ AML CFZ533 OMB157 KAE609 SjS Ped MS Malaria uncomplicated

LNP023 LCM MBG453 LCM ianalumab LCM aHUS Unfit AML VAY736

pSjS NEW INDICATIONS

42 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis submission schedule Supplementary indications for existing brands

2020 2021 2022 2023 ≥2024

alpelisib, BYL719 LCM Kymriah LCM Kisqali LCM Lutathera LCM Jakavi LCM Kymriah LCM Cosentyx LCM Aimovig LCM PROS tisagenlecleucel-T, CTL019 ribociclib, LEE011 177Lu-oxodotreotideb) ruxolitinib, INC424 tisagenlecleucel-T, CL019 secukinumab, AIN457 erenumab, AMG334 r/r DLBCL 1st relapse HR+/HER2- BC (adj) GEP-NET 1L G3 Pediatrics Chronic GVHD r/r DLBCL (+ pembro) GCA Pediatric Migraine

Kymriah LCM Promacta LCM Piqray LCM Jakavi LCM Kymriah LCM Cosentyx LCM Mayzent LCM tisagenlecleucel-T, CTL019 eltrombopag, ETB115 alpelisib, BYL719 ruxolitinib, INC424 tisagenlecleucel-T, CTL019 secukinumab, AIN457 siponimod, BAF312 r/r Follicular lymphoma Radiation sickness syndrome TNBC Pediatrics Acute GVHD 1L high risk ALL, pediatrics & young adults Lichen Planus Pediatric MS

Tafinlar LCM Adakveo LCM Piqray LCM Jakavi LCM Piqray LCM Cosentyx LCM dabrafenib, DRB436 crizanlizumab, SEG101 alpelisib, BYL719 ruxolitinib, INC424 alpelisib, BYL719 secukinumab, AIN457 HGG/LGG - Pediatrics Sickle cell anaemia new formulations HER2+ adv BC Myelofibrosis (combination) HNSCC 2/3L Lupus Nephritis

Promacta LCM Cosentyx LCM Piqray LCM eltrombopag, ETB115 secukinumab, AIN457 alpelisib, BYL719 Food effect free formulation SpA IVIV Ovarian cancer

Jakavi LCM Cosentyx LCM Tafinlar LCM ruxolitinib, INC424 secukinumab, AIN457 dabrafenib, DRB436 Chronic GVHD Hidradenitis suppurativa Tyroid cancer

Jakavi LCM Cosentyx LCM Beovu LCM ruxolitinib, INC424 secukinumab, AIN457 brolucizumab, RTH258 Acute GVHD AS H2H Diabetic retinopathy

Beovu LCM Xolair LCM Beovu LCM brolucizumab, RTH258 omalizumab, IGE025 brolucizumab, RTH258 DME Food allergy RVO a AVXS-101 LCM Entresto EU LCM Coartem LCM onasemno-gene abepar-vovec, OAV101 sacubitril/valsartan, LCZ696 artemether + lumefantrine, CCA566 SMA IT Pediatric HF Malaria uncomplicated, <5kg patients

Xolair LCM denosumab BioS omalizumab, IGE025 GP2411 Auto-injector anti RANKL mAb

Entresto LCM sacubitril/valsartan, LCZ696 Post-AMI

a. Approved in US. b.177Lu-dotatate in US.

43 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis pipeline in registration 3 lead indications Lead indication

Oncology Respiratory Disease Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) PIK3CA mutant HR+, HER2 (-) postmenopausal adv BC 2nd line IGE025 Xolair IgE Inhibitor Nasal polyps BYL719 Piqray PI3Kα inhibitor (+fulv) SEG101 Adakveo® P-selectin Inhibitor Sickle cell disease

Immunology, Hepatology, Dermatology Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) AIN457 Cosentyx IL17A Inhibitor Ped Psoriasis 2ml Auto-injector KJX839 inclisiran siRNA (regulation of LDL-C) Hyperlipidemia LCZ696 Entresto Angiotensin II Receptor HFpEF Neprilysin Inhibitor (ARNI)

Neuroscience Global Health Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) OMB157 ofatumumab CD20 Antagonist r MS LAM320 Lamprene® SMPD1 Inhibitor Tuberculosisa)

a) WHO Pre-Qualification

44 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 3 6 lead indications Lead indication

Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) 177Lu-PSMA-617 177Lu-PSMA-617 Targeted Radioligand Therapy mCRPC AMG334 Aimovig® CGRPR antagonist Ped Migraine 177Lu- BAF312 Mayzent® S1P1 Modulator Ped MS 3) Lutathera® Targeted Radioligand Therapy GEP-NET 1L G3 oxodotreotide OAV101 AVXS-101 Gene Therapy, Survival motor SMA IT 1) ABL001 asciminib BCR-ABL Inhibitor CML 3L neuron (SMN1) gene Adjuvant OMB157 ofatumumab CD20 Antagonist Ped MS ACZ885 canakinumab IL-1b Inhibitor NSCLC 1L NSCLC 2L NSCLC BYL719 Piqray® PI3Kα inhibitor HER2+ adv BC TNBC HNSCC 2/3L Ovarian cancer CTL019 Kymriah CD19 CART r/r Follicular 1L high risk r/r DLBCL 1st Respiratory Disease lymphoma ALL, pediatrics relapse Code Name Mechanism Indication(s) and young adults IGE025 omalizumab IgE Inhibitor Food allergy Auto-injector ETB115 Promacta® Thrombopoietin receptor (TPO-R) Radiation sickness syndrome Food effect free formulation INC424 Jakavi® JAK1 Inhibitor COVID-19 related pneumonia Agonist INC424 Jakavi JAK1/JAK2 Inhibitor Acute GVHD Chronic GVHD Cardiovascular, Renal, Metabolism LEE011 Kisqali® CDK4 Inhibitor HR+/HER2- BC (adj) MBG453 MBG453 TIM3 Antagonist HR-MDS Code Name Mechanism Indication(s) PDR001 Spartalizumab PD1 Inhibitor m BRAF V600+ melanoma (+Taf/Mek) Solid tumors KJX839 inclisiran siRNA (regulation of LDL-C) CVRR-LDLC SEG101 crizanlizumab P-selectin Inhibitor Sickle cell anemia new formulation LCZ696 Entresto® Angiotensin II Receptor Neprilysin Inhibitor Post-AMI Pediatric HF 2) (ARNI) TQJ230 TQJ230 Anti-Apo(a) ASO targeting Lp(a) CVRR-Lp(a) Immunology, Hepatology, Dermatology Code Name Mechanism Indication(s) Global Health AIN457 Cosentyx IL17A Inhibitor Lupus Nephritis Hidradenitis AS H2H SpA IVIV suppurativa Code Name Mechanism Indication(s) ACZ885 canakinumab IL-1b Inhibitor COVID-19 induced respiratory disease COA566 Coartem® - Malaria uncomplicated, <5kg patients QGE031 ligelizumab IgE Inhibitor Chronic urticaria

Ophthalmology Biosimilars Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) RTH258 Beovu® VEGF Inhibitor Diabetic retinopathy RVO DME GP2411 denosumab anti RANKL mAb Denosumab BioS

1) FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study 2) Approved in US 3) 177Lu-dotatate in US 45 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 2 30 lead indications Lead indication

Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BYL719 alpelisib PI3Kα inhibitor PROS BAF312 Mayzent® S1P1 Modulator Stroke BLZ945 BLZ945 - Solid tumors BLZ945 BLZ945 CSF-1 Inhibitor ALS CTL019 Kymriah CD19 CART r/r DLBCL (+ pembro) LMI070 branaplam Survival motor neuron protein SMA EGF816 nazartinib+capmatinib Opdivo EGFR Inhibitor NSCLC (combo) MIJ821 MIJ821 NR2B Inhibitor Depression INC280 capmatinib Met Inhibitor NSCLC EU1) Solid tumors NSCLC Met Inhibitor + spartalizumab HCC INC424 Jakavi® JAK1/JAK2 Inhibitor Myelofibrosis (combination) LAG525 LAG525 LAG3 Inhibitor Solid Tumors Respiratory Disease MBG453 MBG453 TIM3 Antagonist Unfit AML Code Name Mechanism Indication(s) NIR178 NIR178, spartalizumab Ad2AR Inhibitor, PD1 Inhibitor Cancers CSJ117 CSJ117 TSLP Inhibitor Asthma PDR001 spartalizumab PD1 Inhibitor Metastatic melanoma (combo) DFV890 DFV890 - COVID-19 related pneumonia SEG101 crizanlizumab P-selectin Inhibitor Ped sickle cell anaemia with LOU064 remibrutinib BTK Inhibitor Asthma crisis MAS825 MAS825 COVID-19 related pneumonia QBW251 QBW251 CFTR Potentiator COPD VAY736 ianalumab BAFF-R Inhibitor IPF Immunology, Hepatology, Dermatology Code Name Mechanism Indication(s) ADTP02 ADTP02 - NASH (Combos) Cardiovascular, Renal, Metabolism AIN457 Cosentyx® IL17A Inhibitor GCA Lichen Planus CFZ533 iscalimab CD40 Inhibitor Renal/Liver Tx SjS HS Code Name Mechanism Indication(s) LJC242 tropifexor&cenicriviroc CCR2 Inhibitor, FXR agonist NASH (combos) CFZ533 iscalimab CD40 Inhibitor Lupus Nephritis T1DM LJN452 tropifexor FXR agonist NASH NASH (combos) LCZ696 Entresto® Angiotensin II Receptor nHCM Neprilysin Inhibitor (ARNI) LNA043 LNA043 ANGPTL3 Agonist Osteoarthritis LMB763 nidufexor FXR Agonist Diabetic Nephropathy LOU064 remibrutinib BTK Inhibitor CSU SjS LNP023 LNP023 CFB Inhibitor PNH IgAN C3G iMN aHUS LYS006 LYS006 Anti-inflammatory Acne Colitis ulcerative HS LTW980 LTW980 - Hypertriglyceridemia VAY736 ianalumab BAFF-R Inhibitor pSjS AIH SLE

Ophthalmology Global Health Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CPK850 CPK850 RLBP1 AAV RP AFQ056 AFQ056 mGluR5 Antagonist Addiction ECF843 ECF843 rh-Lubricin Dry eye KAE609 cipargamin PfATP4 inhibitor Malaria severe Malaria uncomplicated LKA651 LKA651 EPO Inhibitor DME KAF156 ganaplacide - Malaria uncomplicated SAF312 SAF312 TRPV1 Antagonist COSP LXE408 LXE408 Protozoan Inhibitor Visceral leishmaniasis UNR844 UNR844 disulfide bonds Modulator Presbyopia

46 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation1) Approved in US & JP Novartis pipeline in Phase 1 (1 of 2) 37 lead indications Lead indication

Oncology Code Name Mechanism Indication(s) 177Lu-NeoB 177Lu-NeoB Radioligand therapy target GRPR Multiple solid tumors 177Lu-PSMA-R2 177Lu-PSMA-R2 Radioligand therapy target PSMA Prostate cancer ADPT01 NIR178, LAG525, spartalizumab, canakinumab, capmatinib LAG3 Inhibitor,PD1 Inhibitor TNBC CSJ137 CSJ137 Growth Factor Inhibitor Anaemia CTL019 Kymriah® CD19 CART Lymphoma r/r DLBCL (+ pembro) DKY709 DKY709 + spartalizumab - Cancers EGF816 nazartinib + LXH254, ribociclib, capmatinib, Opdivo, Mekinist EGFR Inhibitor NSCLC (combo) HDM201 HDM201 + MBG453, venetoclax MDM2 Inhibitor Haematological malignancy INC424 Jakavi JAK1/JAK2 Inhibitor Myelofibrosis (combination) JEZ567 JEZ567 CD123 CART AML KAZ954 KAZ954 - Solid tumors LHC165 LHC165 + spartalizumab TLR7 Agonist Solid tumors LXF821 LXF821 EGFR CART Glioblastoma multiforme LXH254 LXH254 (combos) cRAF Inhibitor Solid tumors Solid tumors MAK683 MAK683 EED Inhibitor Cancers MBG453 MBG453 (combos) TIM3 Antagonist Cancers MCM998 MCM998, LXG250 BCMA CART, CD19 CART Multiple myeloma MIK665 MIK665 MCL1 Inhibitor Haematological malignancy AML (combo) NIS793 NIS793, spartalizumab TGFB1 Inhibitor Solid tumors NIZ985 NIZ985, spartalizumab IL-15 Agonist Solid tumors NJH395 NJH395 - Solid tumors NZV930 NZV930, spartalizumab, NIR178 CD73 Antagonist Solid tumors PDR001 spartalizumab (combos) PD1 Inhibitor AML Solid tumors (combo) SQZ622 SQZ622 CD123xCD3 Modulator AML TNO155 TNO155 SHP2 Inhibitor Solid tumors (single agent) Solid tumors (combo) Solid tumors (combo) VAY736 ianalumab + ibrutinib BAFF-R Inhibitor Haematological malignancy VOB560 VOB560 - Cancers VPM087 VPM087 IL1B Antagonist 1st line CRC / 1st line RCC WNT974 WNT974 + spartalizumab Porcupine Inhibitor Solid tumors WVT078 WVT078 - Multiple myeloma YTB323 YTB323  ibrutinib CD19 CART Haematological malignancy

47 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Novartis pipeline in Phase 1 (2 of 2) 37 lead indications Lead indication

Immunology, Hepatology, Dermatology Global Health Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CEE321 CEE321 Pan JAK Inhibitor AD KAF156 ganaplacide - Malaria prophylaxis DFV890 DFV890 - Anti-inflammatory therapy FIA586 FIA586 - NASH LRX712 LRX712 - Osteoarthritis MAS825 MAS825 - Inflammatory diseases MHS552 MHS552 - Autoimmune Indications MHV370 MHV370 - SjS SLE

Neuroscience Code Name Mechanism Indication(s) OAV201 AVXS-201 MECP2 gene therapy Rett syndrome

Respiratory Disease Code Name Mechanism Indication(s) CMK389 CMK389 IL-18 Inhibitor Sarcoidosis LTP001 LTP001 - Respiratory Diseases

Cardiovascular, Renal, Metabolism Code Name Mechanism Indication(s) HSY244 HSY244 - Atrial fibrillation MBL949 MBL949 - Diabetes

1. FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study

48 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation References

Slide 5 Slide 24 nr-axSpA Non-radiographic axial spondyloarthritis RCT Randomized Controlled Clinical Trial PsO Psoriasis PedPsO Pediatric psoriasis PedPsO Pediatric Psoriasis aBC Advanced breast cancer HS Hidradenitis Suppurativa CRSwNP Severe chronic rhinosinusitis with nasal polyps PsA Psoriatic Arthritis LIC / LMICs Low income / lower middle-income countries AS Ankylosing Spondylitis 1 Refers to continuing operations as defined on nr-axSpA non-radiographic Aaxial Spondyloarthritis page 42 of the Condensed Interim Financial jPsA & ERA Juvenile arthritis / enthesitisrelated arthritis Report, excludes Alcon, includes the GCA GCA = Giant Cell Arteritis businesses of Innovative Medicines and Sandoz, as well as the continuing corporate WW WW = Worldwide functions 1 Based on ‘WW IQVIA total brand sales’ and ‘Indication level brand data for G6 PSO (2019)’; 2 Bx treated : DRG + IQVIA patient equivalents (2019); 2 COVID-19 Good Practice Guidance 3 Evaluate Pharma, SpA Market – Bx & Orals (2019); distributed to suppliers 4 PsA and axial SpA: Epidemiology, diagnosed, treated and Bx pool and aligned with DRG, latest CPO inputs 3 Readout expected H2 2020. Discontinued (internal assumption based multiple data sources) (2019) hydroxychloroquine clinical trial for COVID-19 5 Referring to US+EU5 countries due to acute enrollment challenges but 6 Corrona LLC, data on file. Corrona Report: Real-World Data from the Corrona Psoriasis Registry®. June continue to supply the drug for ongoing 15, 2018. Study names investigator-initiated trials and upon government requests 7 CLEAR, CLARITY 8 SCALP, TRANSFIGURE, GESTURE 4 This is addition to previously announced USD 9 MEASURE 40m COVID-19 response funds to support 10 EXCEED, FUTURE public / community health initiatives, healthcare infrastructures and various industry 11 Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic collaborations arthritis with pharmacological therapies: 2019 update Annals of the Rheumatic Diseases 2020;79:700-712 12 MAXIMISE, ULTIMATE, SERENA

49 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Clinical Trials Update

Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2 or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com Cardiovascular, Renal and Metabolic Entresto® - Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT02678312 PANORAMA HF (CLCZ696B2319) NCT03785405 (CLCZ696B2319E1 – extension study) Indication Heart failure in pediatric patients Heart failure in pediatric patients

Phase Phase 2/3 Phase 3

Patients 360 240 Part 1: Pharmacodynamics and pharmacokinetics of Primary Outcome Number of participants with Adverse Events (AEs) and sacubitril/valsartan LCZ696 analytes Measures Serious Adverse Events (SAEs) Part 2: Efficacy and safety compared with enalapril • Part 1: Sacubitril/valsartan 0.8 mg/kg or 3.1 mg/kg or both; 0.4 mg/kg or 1.6 mg/kg or both (single doses). • Part 2: enalapril/placebo 0.2 mg/kg bid (ped. formulation • Single arm, open label sacubitril/valsartan (pediatric 1mg/ml) and adult formulation (2.5, 5, 10 mg bid); formulation granules (12.5, 31.25 mg in capsules); liquid Arms/Intervention Sacubitril/valsartan (LCZ696)/placebo: Ped. formulation formulation (1mg/ml and 4mg/ml concentration) and granules (12.5, 31.25 mg in capsules); liquid formulation adult formulation (50, 100, 200 mg bid)) (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid) Pediatric patients from 1 month to < 18 years of age with Pediatric patients with heart failure due to systemic left Target Patients heart failure due to systemic left ventricle systolic ventricle systolic dysfunction who have completed study dysfunction CLCZ696B2319 H2-2021; (Analysis of 110 pts from Part 2 formed the basis for pediatric submission in Apr-2019 and approval by the US Expected Completion FDA in Oct-2019 for the treatment of symptomatic HF with 2022 systemic left ventricular systolic dysfunction in children aged 1 year and older) Publication TBD TBD 52 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Entresto® - Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT02884206 PERSPECTIVE (CLCZ696B2320) NCT02468232 PARALLEL-HF (CLCZ696B1301) Indication Heart failure Heart failure, reduced ejection fraction

Phase Phase 3 Phase 3

Patients 592 225 Time to the first occurrence of the composite endpoint - Primary Outcome Change from baseline in the CogState Global Cognitive either cardiovascular (CV) death or heart failure (HF) Measures Composite Score (GCCS) hospitalization • Sacubitril/valsartan 50, 100, and 200 mg bid with • Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid/placebo placebo of valsartan of enalapril Arms/Intervention • Valsartan 40, 80, and 160 mg bid tablets with placebo • Enalapril 2.5 mg, 5 mg, 10 mg bid / placebo of for sacubitril/valsartan sacubitril/valsartan

Patients with chronic heart failure with preserved ejection Japanese heart failure patients (NYHA Class II-IV) with Target Patients fraction reduced ejection fraction

Expected Completion 2022 Q1-2019 (actual); H1-2021 (open-label extension)

Publication TBD Planned in Q3-2020: Primary manuscript in Circ J

53 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Entresto® - Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT01920711 PARAGON-HF (CLCZ696D2301) NCT03066804 PARALLAX (CLCZ696D2302) Indication Heart failure, preserved ejection fraction Heart failure, preserved ejection fraction Phase Phase 3 Phase 3 Patients 4,822 2,572

Cumulative number of primary composite events of Change in NT-proBNP from baseline to week 12 Primary Outcome cardiovascular (CV) death and total (first and recurrent) HF and change in 6 minute walk distance (6MWD) from Measures hospitalizations baseline to Week 24

• Sacubitril/valsartan 50 mg, 100 mg and 200 mg bid and matching placebo • Sacubitril/valsartan or placebo 50 mg, 100 mg, and 200 • Enalapril 2.5 mg, 5 mg and 10 mg bid and matching Arms/Intervention mg bid placebo • Valsartan or placebo 40 mg, 80 mg, and 160 mg bid • Valsartan 40 mg, 80 mg, 160 mg bid and matching placebo

Heart failure patients (NYHA Class II-IV) with preserved Heart failure patients (NYHA Class II-IV) with preserved Target Patients ejection fraction ejection fraction

Expected Completion 2019 (actual) 2019 (actual) • Sep-2019: Primary manuscript (ARNI in HFpEF. Solomon S et al; NEJM. DOI: 10.1056/NEJMoa1908655) • Mar-2020: Published (NTproBNP, putative placebo • May-2020 – Published: Study design (Wachter et al; analysis); ESC-HF) Publication • Jun-2020: Submitted (renal outcomes, cognitive • Aug-2020 – Planned: Primary data presentation at ESC function); latebreaker; Publication EHJ Q3-2020. • Q3/Q4-2020 Planned: Urgent HF visits, regional • Q3-2020 – Planned: Baseline data publication differences, win ratio, adjudicated vs reported endpts; Subgroups (mode of death, MRA, age, gender). 54 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Entresto® - Angiotensin II Receptor Neprilysin Inhibitor (ARNI)

Study NCT03909295 (CLCZ696D1301E1 – extension study) NCT02924727 PARADISE-MI (CLCZ696G2301) Indication Heart failure chronic Post-acute myocardial infarction Phase Phase 3 Phase 3 Patients 52 5,670

Time to the first occurrence of a confirmed composite Primary Outcome Number of participants with Adverse Events (AEs) and endpoint (cardiovascular (CV) death, heart failure (HF) Measures Serious Adverse Events (SAEs) hospitalization, or outpatient heart failure)

• Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid / placebo • Sacubitril/valsartan 50 mg,100 mg,200 mg film coated of ramipril/valsartan Arms/Intervention tablets • Ramipril 1.25 mg, 2.5 mg, and 5 mg bid / placebo of sacubitril/valsartan / placebo for valsartan

Japanese heart failure patients (NYHA Class II-IV) with Post-AMI patients with evidence of LV systolic dysfunction Target Patients preserved ejection fraction after CLCZ696D2301 and/or pulmonary congestion, with no known prior history of (PARAGON-HF) chronic HF

Expected Completion Q4-2019 (actual) H1-2021 • Q3-2020 – Planned: PARADISE-MI study design; Publication TBD • Q4-2020 – Planned; PARADISE-MI baseline chars

55 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation KJX839 – siRNA (regulation of LDL-C)

Study NCT03060577 ORION-3 (CKJX839A12201E1) NCT03814187 ORION-4 (CKJX839A1KJX839B12301) Hypercholesterolemia inc. Atherosclerotic Cardiovascular Hypercholesterolemia inc. Heterozygous Familial Indication Disease (ASCVD) and ASCVD risk equivalents Hypercholesterolaemia (HeFH) Heterozygous Familial Hypercholesterolaemia (HeFH) Phase Phase 2 Phase 3 Patients ~374: 284 in Group 1 and 90 in Group 2 ~15,000 A composite of major adverse cardiovascular events, LDL-C reduction at Day 210 for Group 1 subjects defined as: Primary Outcome Changes in other lipids and lipoproteins and reduction of • Coronary heart disease (CHD) death; Measures LDL-C of more than 50% for patients that are above LDL-C • Myocardial infarction; goal ; longer term exposure and safety. • Fatal or non-fatal ischaemic stroke; or • Urgent coronary revascularization procedure • Group 1 – inclisiran 300mg sc every 6 months until day Arm 1: every 6 month treatment KJX839 300mg (given by 720 and then on Day 810, followed by every 6 months for a subcutaneous injection on the day of randomization, at 3 planned duration of 4 years months and then every 6-months) for a planned median Arms/Intervention • Group 2- Evolocumab 140mg s.c. injection every 2 duration of about 5 years weeks for 360 days, followed by inclisiran 300mg on Day Arm 2: matching placebo (given bysubcutaneous injection 360, Day 450 and then every 6 months for a planned on the day of randomization, at 3 months and then every 6- duration of 4 years. months) for a planned median duration of about 5 years.

Patient population with mean baseline LDL-C ≥ 100mg/dL; Patients with HeFH or pre-existing atherosclerotic long- 5 year- follow-up time is designed to show best in- Target Patients cardiovascular disease (ASCVD) on background statin +/- class CV outcomes (25% benefit). ezetimibe therapy

Expected Completion 2022 2025 Publication TBD TBD 56 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation KJX839 – siRNA (regulation of LDL-C)

Study NCT03851705 ORION-5 (CKJX839A12304) NCT03399370 ORION-8 (CKJX839A12305B) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolemia inc. Homozygous Familial Indication Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Hypercholesterolemia (HoFH) Phase Phase 3 Phase 3 Patients 56 randomized 2:1 (inclisiran: placebo) 2967 entered the study The effect of inclisiran treatment on the proportion of LDL-C reduction at Day 150 Primary Outcome subjects achieving prespecified low density lipoprotein Changes in PCSK9, other lipids and lipoproteins and Measures cholesterol(LDL-C)targets at end of study. The safety and reduction of LDL-C of more than 20% tolerability profile of long term use of inclisiran • Part 1: inclisiran 300mg on Day 1 and Day 90 or placebo on Day 1 and Day 90 Inclisiran 300mg on day 1 (placebo patients in feeder study) • Part 2: inclisiran on Day 180 for patients who were or placebo on Day 1 (inclisiran patients in feeder study ) Arms/Intervention randomized to the placebo group only, inclisiran on Day then inclisiran 300mg on Day 90 and every 6 months for a 270 and then every 6 months for a planned duration of 2 planned duation of 3 years years for all patients Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- Target Patients Patients with HoFH ezetimibe therapy and risk equivalents (patients from ORION 9, 10 & 11 studies) Expected Completion Primary: Q3-2020; Final: H2-2021 2023 Publication TBD TBD

57 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03373461 (CLNP023X2203) NCT04154787 (CLNP023D12201) Indication IgA nephropathy (IgAN) Idiopathic membranous nephropathy (iMN) Phase Phase 2 Phase 2 Patients 146 72

Primary Outcome Change from baseline of log transformed UPCR derived from Change from baseline of UPCR derived from 24hr urine Measures the 24h urine collections at Baseline and Day 90 collections at Baseline and Week 24

• Placebo • LNP023 Dose 1 – 10mg bid • LNP023 Dose – 200mg bid Arms/Intervention • LNP023 Dose 2 – 50mg bid • LNP023 Dose – 50mg bid • LNP023 Dose 3 – 200mg bid • Rituximab • LNP023 Dose 4 – 100mg bid (Part 2 only)

Patients with biopsy proven iMN who are at high risk of Target Patients Patients with biopsy-verified IgA nephropathy disease progression defined on the basis of antibody anti- PLA2R titre and proteinuria

Expected Completion H2-2021 2022 Publication TBD TBD

58 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03832114 (CLNP023X2202) NCT03955445 (CLNP023B12001B) Indication C3 glomerulopathy (C3G) C3 glomerulopathy (C3G) Phase Phase 2 Phase 2 (open-label extension) Patients 27 27 (from ongoing Phase 2, potential patient from Ph3) Cohort A: Ratio to Baseline of UPCR to Week 12 derived Characterize the effect of LNP023 treatment on a composite from 24hr urine collection renal response endpoint at 9 months (1. a stable or Primary Outcome Cohort B: Change from Baseline in C3 Deposit Score improved eGFR and, 2. a reduction in proteinuria and 3. an Measures (based on immunofluorescence microscopy) at Week 12 increase in C3 compared to the CLNP023X2202 baseline visit)

Increasing doses of LNP023 up to 200mg bid: Arms/Intervention • Cohort A: Native kidney patients • Open-label LNP023 200mg bid • Cohort B: Kidney transplanted patients

Target Patients Patients with C3 glomerulopathy Patients with C3 glomerulopathy

Expected Completion H1-2021 2025 Publication TBD TBD

59 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LNP023 – Factor B inhibition of the complement alternative pathway

Study NCT03439839 (CLNP023X2201) NCT03896152 (CLNP023X2204) Indication Paroxysmal nocturnal hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) Phase Phase 2 Phase 2 Patients 15 10

Reduction of PNH associated hemolysis, based on Primary Outcome Reduction of chronic hemolysis, based on LDH level at percentage of patients with 60% reduction in LDH or LDH Measures Week 13 below upper limit of normal up to 12 weeks of treatment.

• Cohort 1: 10 patients receiving LNP023 200mg bid, in addition to SoC, for 13 weeks with 3yr treatment extension • Arm 1: 4wks treatment LNP023 25mg bid followed by period 8wk treatment LNP023 100mg bid and 2yr extension • Cohort 2: 5 patients receiving LNP023 50mg bid, in LNP023 100mg bid Arms/Intervention addition to SoC, for minimum 2 weeks with 3yr treatment • Arm 2: 4wks treatment LNP023 50mg bid followed by extension period. Dose may be increased D15 onwards to 8wk treatment LNP023 200mg bid and 2yr extension 200mg bid if LDH not within limit of normal or reduced by at LNP023 200mg bid least 60% compared to Baseline.

Patients with PNH, showing signs of active hemolysis Patients with PNH, showing signs of active hemolysis, not Target Patients despite treatment with SoC (defined as an antibody with anti treated with any other complement inhibitor less than 3 C5 activity). months prior to study start Day 1

Primary endpoint: Q2-2020 Primary endpoint: Q2-2020 Expected Completion Extension period: 2023 Extension period: 2022 Publication In preparation (PoC study) TBD

60 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation TQJ230 – Antisense oligonucleotide targeting apolipoprotein(a) mRNA

Study NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Cardiovascular risk reduction Phase Phase 3 Patients 7,680

Time to the first occurrence of MACE (cardiovascular death, Primary Outcome non-fatal MI, non-fatal stroke and urgent coronary re- Measures vascularization)

Arms/Intervention TQJ230 80 mg injected monthly subcutaneously or matched placebo

Patients with a history of Myocardial infarction or Ischemic Target Patients Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Expected Completion 2024 Publication TBD

61 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Immunology, Hepatology & Dermatology CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody Study NCT03663335 CIRRUS I (CCFZ533A2201) NCT03905525 TWINSS (CCFZ533B2201)

Indication Kidney transplantation Sjögren's syndrome

Phase Phase 2B Phase 2B

Patients 676 260

Composite event (BPAR, Graft Loss or Death) over 12 Change in EULAR Sjögren’s syndrome Disease Activity Primary Outcome months post-transplantation and post conversion (for Index (ESSDAI) score and EULAR Sjögren’s syndrome Measures maintenance cohort) Patient Reported Index (ESSPRI) score • Two cohorts: de novo TX and maintenance • Three dose arms of CFZ533 Arms/Intervention • Test Arms: CFZ533 + MMF + corticosteroids • Placebo • Standard of Care: TAC + MMF + corticosteroids Target Patients Kidney transplant recipients Patients with Sjögren's syndrome

Expected Completion 2022 2023 Manuscript of PoC trial published in The Lancet- Publication Manuscript of PoC trial to be submitted in Q1-2020 Rheumatology January 23, 2020

63 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation CFZ533 – Blocking, non-depleting, Fc-silent, anti-CD40 monoclonal antibody Study NCT03781414 CONTRAIL I (CCFZ533A2202)

Indication Liver transplantation

Phase Phase 2

Patients 128

Primary Outcome Proportion of patients with composite event (BPAR, Graft Measures Loss or Death) over 12 months

• Control/Standard of Care: TAC + MMF + Corticosteroids Arms/Intervention • CFZ533 dose A + MMF + Corticosteroids • CFZ533 dose B + MMF + Corticosteroids Target Patients Liver transplant recipients

Expected Completion 2023

Publication TBD

64 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03504852 (CAIN457A2324) NCT03589885 MATURE (CAIN457A2325) Indication Psoriasis Psoriasis Phase Phase 3B Phase 3 Patients 331 122

Primary Outcome PASI 90 response and IGA mod 2011 0 or 1 response after PASI 75 response and IGA mod 2011 0 or 1 response after Measures 16 weeks of treatment 12 weeks of treatment

• Secukinumab 300 mg every 2 weeks after weekly doses • Secukinumab 2 mL (300 mg) auto-injector till Week 4 • Secukinumab 2 x 1 mL (150 mg each) prefilled syringe Arms/Intervention • Secukinumab 300 mg every 4 weeks after weekly doses • Placebo 2 mL auto-injector till Week 4 • Placebo 2 x 1 mL prefilled syringe

Target Patients Subjects (≥90kg) with moderate to severe plaque psoriasis Subjects with moderate to severe plaque psoriasis

Expected Completion Q3-2020 Q4-2020

Publication TBD TBD

65 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02471144 (CAIN457A2310) NCT03668613 (CAIN457A2311) Indication Psoriasis Psoriasis Phase Phase 3 Phase 3 Patients 162 84 Psoriasis Area and Severity Index (PASI) 75 response and Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12 week 12

• Secukinumab low dose • Secukinumab high dose • Secukinumab low dose Arms/Intervention • Placebo • Secukinumab high dose • Etanercept (comparator)

Patients from 6 to less than 18 years of age with severe Pediatric patients of age 6 to <18 years, with moderate to Target Patients chronic plaque psoriasis severe plaque psoriasis Expected Completion 2023 2023

Publication TBD TBD

66 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03066609 (CAIN457A2318) Indication Psoriasis

Phase Phase 3

Patients 543 Psoriasis Area and Severity Index (PASI) 75 response and Primary Outcome Investigators' Global Assessment (IGA) 0 or 1 response at Measures week 12

• Secukinumab 300 mg Arms/Intervention • Secukinumab 150 mg • Placebo

Patients with moderate to severe chronic plaque-type Target Patients psoriasis with or without psoriatic arthritis comorbidity

Expected Completion Q1-2019 (actual) • Week 16 results: Poster presented at: 2019 American Academy of Dermatology (AAD) Annual Meeting, • March 1–5, 2019, Washington, D.C. Publication • 52-week results: Poster at EADV 2019, Madrid 9-13 October, 2019 • Manuscript Publication under assessment

67 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03031782 (CAIN457F2304) NCT03769168 (CAIN457F2304E1 – extension study) Indication Psoriatic arthritis Psoriatic arthritis Phase Phase 3 Phase 3 Patients 80 64

Primary Outcome Time to 33 flares Number of participants with JIA ACR30 response Measures

• Secukinumab (pre-filled syringe) 75 mg • Secukinumab 75 mg/0.5 ml Arms/Intervention • Placebo • Secukinumab 150 mg/1.0 ml

Juvenile idiopathic arthritis subtypes of psoriatic and Patients with juvenile idiopathic arthritis subtypes of juvenile Target Patients enthesitis-related arthritis psoriatic arthritis and enthesitis related arthritis Expected Completion H1-2021 2025

Publication TBD TBD

68 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01892436 FUTURE 1 extension (CAIN457F2306E1) NCT01649375 MEASURE 2 (CAIN457F2310) Indication Psoriatic arthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 460 219 Proportion of subjects that have a positive clinical response Primary Outcome Assessment of SpondyloArthritis International Society / to treatment (individual improvement) in disease activity Measures ASAS 20 response according to ACR20 (or ACR50 or ACR 70)

• Secukinumab 75 mg • Secukinumab 75 mg Arms/Intervention • Secukinumab 150 mg • Secukinumab 150 mg • Placebo

Target Patients Patients with active psoriatic arthritis Patients with active ankylosing spondylitis Expected Completion 2018 (actual) 2018 (actual) • Primary 52 week results: Baeten D & Sieper J, et al. N Engl J Med 2015;373:2534–48 • 3 year results: ACR 2016; Mease PJ et al. Arthritis • 2 year results: Marzo-Ortega, et al. Arthritis Care Res Rheumatol. 2016; 68 (suppl 10) 2017 Feb 24. doi: - 10.1002/acr.23233 • 3 years results: Manuscript published in September • 3 year results: Marzo-Ortega, et al. RMD 2017 Publication 2018 (Mease PJ, et al. RMD Open 2018;4:e000723. • 5 year results: EULAR 2019; Marzo-Ortega H, et al. doi:10.1136/rmdopen-2018-000723) FRI0379. Annals of the Rheumatic Diseases • 5 year results: Published in ACR Open Rheumatology. 2019;78:873. November 14, 2019 • 5 year results; Published in Lancet Rheumatology, June 2020

69 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT01752634 FUTURE 2 (CAIN457F2312) NCT02008916 MEASURE 3 (CAIN457F2314) Indication Psoriatic arthritis Ankylosing spondylitis Phase Phase 3 Phase 3 Patients 399 222

Primary Outcome Proportion of subjects achieving American College of Assessment of Spondyloarthritis International Society Measures Rheumatology 20 (ACR20) response criteria criteria / ASAS 20 response

• Secukinumab (AIN457) 150 mg s.c. • Secukinumab 10 mg/kg / 300 mg • Secukinumab (AIN457) 75 mg s.c. Arms/Intervention • Secukinumab 10 mg/kg / 150 mg • Secukinumab (AIN457) 300 mg s.c. • Placebo • Placebo s.c.

Target Patients Patients with active psoriatic arthritis Patients with active ankylosing spondylitis Expected Completion 2019 (actual) 2018 (actual) • 16 weeks results: PANLAR congress in Apr-2016 • 52 weeks results: Pavelka et al. Arthritis Research & • Primary results: McInnes IB, et al. Lancet. Therapy 2017 2015;386:1137–46 • 2 year results: Presented at ACR in Nov-2017 Publication • 2 years results: McInnes et al, Rheumatology • 3 year (EOS) results: To be presented (ORAL) at 2017;56:1993-2003 PANLAR April 2019 • 5 years: published Lancet Rheumatology in March 2020 • 3 year (EOS) manuscript published in ACR Open Rheumatology in January 2020

70 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02745080 EXCEED (CAIN457F2366) Indication Psoriatic arthritis Phase Phase 3 Patients 850

Primary Outcome American College of Rheumatology 20 (ACR20) response Measures

• Secukinumab 300 mg s.c. Arms/Intervention • Adalimumab 40 mg s.c.

Target Patients Patients with active psoriatic arthritis Expected Completion Q1-2020

Publication Published in the Lancet in May-2020

71 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT02696031 PREVENT (CAIN457H2315) NCT03259074 SURPASS (CAIN457K2340)

Indication Non-radiographic axial spondyloarthritis Ankylosing spondylitis

Phase Phase 3 Phase 3

Patients 555 837

The proportion of participants who achieved an ASAS 40 No radiographic structural progression as measured by Primary Outcome response (Assessment of SpondyloArthritis International modified Stoke Ankylosing Spondylitis Spine Score Measures Society criteria); (mSASSS) • Secukinumab 150 mg load • Secukinumab 150/300 mg Arms/Intervention • Secukinumab 150 mg no load • Adalimumab biosimilar 40 mg • Placebo

Target Patients Patients with non-radiographic axial spondyloarthritis Patients with active ankylosing spondylitis

Expected Completion Week 52: Q3-2019 (actual); Final: H1-2021 2022

• Abstract (16 week results) presented at ACR 2019 • Study design manuscript published. Baraliakos et al. Publication • Abstract (52 week results) presented at EULAR 2020 Clinical Drug Investigation (2020) 40:269–278. • Manuscript submitted in Mar-2020 (awaiting decision)

72 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03713619 SUNSHINE (CAIN457M2301) NCT04179175 (CAIN457M2301E1)

Indication Hidradenitis Suppurativa (HS) Hidradenitis Suppurativa (HS)

Phase Phase 3 Phase 3

Patients 471 745

Primary Outcome Proportion of participants with Hidradenitis Suppurativa Proportion of patients with Hidradenitis Suppurativa Clinical Measures clinical response (HiSCR) Response (HiSCR)

• Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 4 weeks • Secukinumab 300 mg every 2 weeks Arms/Intervention • Placebo (every 2 weeks) • Secukinumab 300 mg every 4 weeks • Placebo (every 4 weeks) Patients with moderate to severe hidradenitis suppurativa Target Patients Patients with moderate to severe Hidradenitis Suppurativa completing either of the core trials AIN457M2301 (NCT 0313632) or AIN567M2302 (NCT03713619) Expected Completion Weak 16 DBL: H2-2021; Final: 2022 2025

• Study design SHSA 2020 Publication Study design SHSA 2020 • Preliminary results in AAD (most likely) in 2022

73 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT03713632 SUNRISE (CAIN457M2302)

Indication Hidradenitis Suppurativa (HS)

Phase Phase 3

Patients 471

Primary Outcome Proportion of patients with Hidradenitis Suppurativa Clinical Measures Response (HiSCR)

• Secukinumab 300 mg every 2 weeks • Secukinumab 300 mg every 4 weeks Arms/Intervention • Placebo (every 2 weeks) • Placebo (every 4 weeks) Target Patients Subjects with moderate to severe Hidradenitis Suppurativa

Expected Completion Weak 16 DBL: H2-2021; Final: 2022

• Study design SHSA 2020 Publication • Preliminary results in EADV (most likely) in 2021

74 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Cosentyx® - Anti IL-17

Study NCT04156620 INVIGORATE-1 (CAIN457P12301) NCT04209205 INVIGORATE-2 (CAIN457P12302)

Indication Axial spondyloarthritis Axial spondyloarthritis

Phase Phase 3 Phase 3

Patients 500 380

The proportion of subjects achieving an ASAS40 Primary Outcome The proportion of subjects achieving American College of (Assessment of SpondyloArthritis International Society Measures Rheumatology 50 (ACR50) response criteria criteria) response

• Secukinumab intravenous (i.v.) regimen • Secukinumab intravenous (i.v.) regimen Arms/Intervention • Placebo intravenous (i.v.) regimen • Placebo intravenous (i.v.) regimen

Patients with active psoriatic arthritis (PsA) despite current Target Patients Patients with active axial spondyloarthritis or previous NSAID, DMARD and/or anti-TNF therapy Expected Completion 2022 2022

Publication TBD TBD

75 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Ilaris® - Anti IL-1β

Study NCT02296424 (CACZ885G2306) NCT04362813 CAN-COVID (CACZ885D2310) Indication SJIA - Systemic Juvenile Idiopathic Arthritis COVID-19 induced respiratory disease Phase Phase 3B/4 Phase 3 Patients 182 450 Proportion of patients in clinical remission on canakinumab Number of patients with clinical response; Clinical response Primary Outcome who are able to remain in remission following canakinumab is defined as survival without ever requiring invasive Measures dose tapering (reduced canakinumab dose or prolonged mechanical ventilation from day 3 to day 29 canakinumab dosing interval) • Canakinumab dose reduction • Canakinumab Arms/Intervention • Canakinumab dose interval prolongation • Placebo Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Target Patients Patients With COVID-19-induced pneumonia (Pediatric) Expected Completion 2018 (actual) Q4-2020

• Remission & flexible dosing – presented at ISSAID & EULAR in Q2-2019 Publication Planned manuscript submission in Q4-2020 • Planned manuscript in 2019: Remission & flexible dosing submitted in Q4-2019

76 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LJN452 - FXR Agonist

Study NCT02855164 (CLJN452A2202) NCT04065841 ELIVATE (CLJN452D12201C) Indication Non-alcoholic steatohepatitis (NASH) Non-alcoholic steatohepatitis (NASH)

Phase Phase 2 Phase 2

Patients 345 210 Adverse event profile of different doses; determine the dose relationship of LJN452 on markers of hepatic inflammation Proportion of patients with resolution of NASH and no Primary Outcome in NASH (ALT and AST); determine dose-response worsening of fibrosis OR improvement in fibrosis by at least Measures relationship of LJN452 on liver fat content by changes in one stage without worsening of NASH at Week 48 quantitative MRI; determine effect of LJN452 on liver fibrosis compared with baseline by biopsy • Arm A: combination therapytropifexor + licogliflozin • Arm B: tropifexor monotherapytropifexor (+ licogliflozin Arms/Intervention • Multiple LJN452 doses and placebo placebo) • Arm C: licogliflozin monotherapylicogliflozin (+ tropifexor placebo) Adult patients with non-alcoholic steatohepatitis (NASH) Target Patients Patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis Expected Completion Q2-2020 (actual) 2022 • Primary (interim) data abstract submitted to AASLD in Publication Q3-2019 Planned in H1-2023 • Manuscript to be submitted in Q4-2020

77 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LOU064 – Bruton's tyrosine kinase (BTK) inhibitor

Study NCT03926611 (CLOU064A2201) NCT04109313 (CLOU064A2201E1)

Indication Chronic spontaneous urticaria (CSU) Chronic spontaneous urticaria (CSU)

Phase Phase 2 Phase 2

Patients 308 250

Primary Outcome Change from baseline in weekly Urticaria Activity Score (UAS7) at Week • Long-term safety and tolerability Measures 4

• Arm 1 Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Arm 2 Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 • Arm 3 High dose of LOU064 orally in the morning (once daily) and • Selected dose of LOU064 taken orally twice a day Arms/Intervention matching placebo in the evening from Day 1 to 85 (morning and evening) from day 1 to week 52 • Arm 4 Low dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 5 Medium dose of LOU064 orally, twice daily from Day 1 to 85 • Arm 6 High dose of LOU064 orally, twice daily from Day 1 to 85 • Placebo arm Matching placebo, orally, twice daily from Day 1 to 85 Patients with CSU who have participated in preceding Target Patients Adults with CSU inadequately controlled by H1-antihistamines studies with LOU064 Expected Completion Q2-2021 2022

Publication TBD TBD 78 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LJC242 - FXR agonist + CCR2/CCR5 inhibitor

Study NCT03517540 TANDEM (CLJC242A2201J)

Indication Non-alcoholic steatohepatitis

Phase Phase 2

Patients 193

• Evaluation of safety and tolerability of combination Primary Outcome therapy (tropifexor + cenicriviroc) by monitoring adverse Measures event profile, vital signs and laboratory parameters

• Tropifexor Arms/Intervention • Cenicriviroc • Tropifexor + cenicriviroc Adult patients with non-alcoholic steatohepatitis (NASH) and Target Patients liver fibrosis Expected Completion Q4-2020

Publication Manuscript to be submitted in H1-2021

79 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE Study NCT02477332 (CQGE031C2201) NCT02649218 (CQGE031C2201E1)

Indication Chronic spontaneous urticaria / Chronic idiopathic urticaria Chronic spontaneous urticaria / Chronic idiopathic urticaria

Phase Phase 2B Phase 2B

Patients 382 226

Primary Outcome Establish dose-response relationship of QGE031 with respect to Long-term safety; number of participants with treatment- Measures achievement of complete hives response at week 12 emergent adverse events

• Ligelizumab 24mg q4wks for 20 weeks • Ligelizumab 72mg q4wks for 20 weeks • Ligelizumab 240mg q4wks for 20 weeks Arms/Intervention Ligelizumab 240 mg q4wks open label for 52 weeks • Ligelizumab 120mg single dose • Omalizumab 300mg q4wks for 20 weeks • Placebo q 4wks for 20 weeks

Adult patients with chronic spontaneous urticaria inadequately Adult patients with chronic spontaneous urticaria inadequately controlled with H -antihistamines at approved or increased doses, Target Patients 1 controlled with H -antihistamines at approved or increased alone or in combination with H -antihistamines or leukotriene 1 2 doses, alone or in combination with H -antihistamines or receptor antagonists. 2 leukotriene receptor antagonists. Expected Completion 2017 (actual) 2019 (actual) • Primary results: AAD 2019; • Primary results: Presented at EAACI 2018, EADV 2018, and • Secondary results presented in 2019 at: AAD, EAACI, WCD, GUF 2018; NEJM publication (3 Oct 2019); EADV, PAAM, ACAAI, UCARE • Secondary results presented in 2019 at: AAD, EAACI, WCD, Publication • Exploratory results presented/ planned in 2020: AAAAI, EADV, PAAM, ACAAI, UCARE. EAACI, EADV, ACAAI; Encoring all at GUF • Exploratory results presented/ planned in 2020: AAAAI, • 5 Manuscripts 2020: core results extension; angioedema; EAACI, EADV, ACAAI; Encoring all at GUF sleep/work impairment/rescue medication; data visualization 80 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE

Study NCT03437278 (CQGE031C2202) NCT04210843 (CQGE031C2302E1)

Indication Chronic spontaneous urticaria / Chronic idiopathic urticaria Chronic spontaneous urticaria

Phase Phase 2 Phase 3

Patients 48 800

Primary Outcome The proportion of subjects with well-controlled disease Change in the 7 day Urticaria Activity Score (UAS7) Measures (UAS7 ≤ 6) at week 12

• Ligelizumab high dose q4wks for 24 weeks • Ligelizumab Dose 1 and 3 Arms/Intervention • Ligelizumab low dose q4wks for 24 weeks • Ligelizumab Dose 2 and 3 • Placebo / ligelizumab high dose q4wks for 8 / 16 weeks Adolescents from 12 to <18 years of age, with chronic Patients who completed studies CQGE031C2302, Target Patients spontaneous urticaria CQGE031C2303, CQGE031C2202 or CQGE031C1301 Expected Completion H2-2021 2026 • Study design was presented at PAAM (Peds Allergy & Asthma Meeting) and at UCARE meeting 2019 • Baseline characteristics 2020/21 Publication Study design presented at 2020 EAACI • Primary results to be presented in late 2021/2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

81 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QGE031 - Anti-IgE

Study NCT03580369 Pearl 1 (CQGE031C2302) NCT03580356 Pearl 2 (CQGE031C2303)

Indication Chronic spontaneous urticaria Chronic spontaneous urticaria

Phase Phase 3 Phase 3

Patients 1,050 1,050

Primary Outcome Absolute change from baseline in UAS7 (Urticaria Activity Absolute change from baseline in UAS7 (Urticaria Activity Measures Score) at week 12 Score) at week 12

• Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose A q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks • Ligelizumab dose B q4w for 52 weeks Arms/Intervention • Omalizumab 300 mg q4w for 52 weeks • Omalizumab 300 mg q4w for 52 weeks • Placebo q4w from randomization to wk20, then • Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria Adolescents and adults with chronic spontaneous urticaria Target Patients inadequately controlled with H1-antihistamines inadequately controlled with H1-antihistamines Expected Completion H2-2021 H2-2021 • Study design presented at UCARE 2018 Publication • Primary results to be presented in 2022 (e.g. EAACI, PAAM, EADV) • Manuscript to be submitted in 2022

82 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation VAY736 – Fully human IgG1/κ anti-BAFF-R mAb

Study NCT02962895 (CVAY736A2201) NCT03217422 AMBER (CVAY736B2201)

Indication Primary Sjögren's syndrome Autoimmune hepatitis

Phase Phase 2B Phase 2/3

Patients 180 80

Primary Outcome Safety and efficacy of VAY736 in primary Sjögren's Alanine aminotransferase (ALT) normalization Measures syndrome (pSS)

• VAY736 • VAY736 Arms/Intervention • Placebo • Placebo control with conversion to active VAY736 Patients with moderate to severe primary Sjögren's Autoimmune hepatitis patients with incomplete response or Target Patients syndrome (pSS) intolerant to standard treatment of care Expected Completion Q2-2020 (actual) 2023

Publication • Manuscript to be submitted in 2020 TBD

83 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Neuroscience Aimovig® – CGRP receptor antagonist

Study NCT03096834 LIBERTY (CAMG334A2301) NCT03333109 EMPOWER (CAMG334A2302) Indication Migraine Migraine

Phase Phase 3 Phase 3

Patients 246 900

Primary Outcome Percentage of patients with a 50% response in the reduction Change from baseline in monthly migraine days at the last Measures of Monthly Migraine Days (MMD) month (Month 3) of the double-blind treatment period

• AMG334 (erenumab) Dose 1 • Subcutaneous injection of AMG334 (erenumab) Arms/Intervention • AMG334 (erenumab) Dose 2 • Subcutaneous injection of placebo • Placebo

Adult episodic migraine patients who have failed prophylactic Target Patients Adult episodic migraine patients migraine treatments

Expected Completion 2017 DBT phase (actual); H1-2021 OLE phase (final DBL) Q1-2020 (actual) • Planned for Q1-2020 (Neurology - rejected): PROs and prespecified subgroup analysis (DBT phase) submitted to JNNP in June 2020 Publication Planned for H2-2020 • Planned for Q2-2020: 1Y OLE (submitted to Neurology) • Planned for Q4 2020: 2Y OLE Abstracts completed for EAN, AHS and EHF in 2020

85 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Aimovig® – CGRP receptor antagonist

Study NCT03867201 DRAGON (CAMG334A2304) Indication Migraine

Phase Phase 3

Patients 550

Primary Outcome Change from baseline in monthly migraine days during the Measures last 4 weeks of the 12-week treatment period

• Subcutaneous injection of AMG334 (erenumab) 70 mg Arms/Intervention • Subcutaneous injection of placebo

Target Patients Adult chronic migraine patients

Expected Completion 2022 DBT phase; 2024 OLE phase

Publication Planned in Q3-2022 (DBT) and H1-2025 for OLE

86 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Gilenya® - S1P-R modulator

Study NCT01633112 ASSESS (CFTY720D2312)

Indication Relapsing remitting multiple sclerosis (RRMS)

Phase Phase 3B

Patients 1,064 Comparison of 2 doses (0.25 mg and 0.5 mg) of fingolimod Primary Outcome to glatiramer acetate (20 mg) in reducing the annualized Measures relapse rate up to 12 months • Fingolimod 0.5 mg orally Arms/Intervention • Fingolimod 0.25mg orally • Copaxone® 20 mg s.c.

Target Patients Patients with relapsing-remitting multiple sclerosis

Expected Completion 2018 (actual) • Primary data presentation at AAN in 2019 Publication • Primary manuscript accepted by JAMA Neurology in June 2020

87 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation LMI070 - SMN2 RNA splice modulator

Study NCT02268552 (CLMI070X2201)

Indication Type 1 spinal muscular atrophy

Phase Phase 1/2

Patients 39

Primary Outcome Number of participants with adverse events (AEs), serious Measures adverse events (SAEs) and deaths

Branaplam oral, once weekly: • Part 1: 5 ascending doses Arms/Intervention • Part 2: 2 different dose levels • Part 3: patients continue on initial dose assigned in Part 1 or Part 2 Patients with type 1 spinal muscular atrophy Target Patients

Expected Completion Q3-2020 (Part 2)

Publication TBD

88 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Mayzent ® - S1P-R modulator

Study NCT01665144 -EXPAND (CBAF312A2304) Indication Secondary progressive multiple sclerosis Phase Phase 3 Patients 1,652

The delay in time to confirmed disability progression as Primary Outcome Measures measured by EDSS (Expanded Disability Status Scale)

• BAF312 (5-day titration: 0.25mg to 1.25mg; Maintenance Arms/Intervention dose: 2mg (day 6)) • Placebo

Target Patients Patients with secondary progressive multiple sclerosis

Expected Completion Core in 2016/Extension in 2024 Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 Publication study. Kappos L et al. Lancet 2018; 391:1263-73 DOI: https://doi.org/10.1016/S0140-6736(18)30475-6

89 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation OMB157 - Anti-CD20

Study NCT02792218 Asclepios I (COMB157G2301) NCT02792231 Asclepios II (COMB157G2302) Indication Multiple sclerosis Multiple sclerosis

Phase Phase 3 Phase 3

Patients 900 900

Annualized Relapse Rate (ARR) - number of confirmed Annualized Relapse Rate (ARR) - number of confirmed Primary Outcome relapses in a year calculated based on cumulative number relapses in a year calculated based on cumulative number Measures of relapses by patient adjusted for time-in-study by patient of relapses by patient adjusted for time-in-study by patient

• Ofatumumab subcutaneous • Ofatumumab subcutaneous Arms/Intervention • Teriflunomide oral • Teriflunomide oral

Target Patients Patients with relapsing forms of multiple sclerosis Patients with relapsing forms of multiple sclerosis

Expected Completion Q3-2019 (actual) Q3-2019 (actual)

Publication Primary manuscript planned in H1-2020 Primary manuscript planned in H1-2020

90 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation OMB157 - Anti-CD20

Study NCT03249714 APOLITOS (COMB157G1301) NCT03650114 ALITHIOS (COMB157G2399) Indication Multiple sclerosis Multiple Sclerosis

Phase Phase 2 Phase 3

Patients 60 2010

Reduced cumulative number of Gd-enhanced T1 lesions Evaluate the long-term safety and tolerability of ofatumumab Primary Outcome across 4 MRI scans at week 12, 16, 20 and 24 (ofatumumab 20 mg subcutaneous (sc) once every 4 (q4) weeks in Measures vs placebo) subjects with RMS from the first dose of ofatumumab

• Ofatumumab 20 mg subcutaneous injections Arms/Intervention • Ofatumumab 20 mg every 4 weeks • Placebo

Target Patients Patients with relapsing forms of multiple sclerosis Patients with relapsing MS

2028 Expected Completion Q1-2020 (actual)

Publication TBD TBD

91 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Zolgensma® - SMN1 gene replacement therapy

Study NCT03461289 STRIVE-EU (CL-302) NCT03306277 STRIVE (CL-303) Indication Type 1 spinal muscular atrophy Type 1 spinal muscular atrophy

Phase Phase 3 Phase 3

Patients 33 22

• Achievement of independent sitting for at least 30 Primary Outcome Proportion of participants sitting without support seconds Measures • Event-free survival

Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous

Target Patients Patients with spinal muscular atrophy Type 1 Patients with Spinal Muscular Atrophy Type 1

Expected Completion Q4-2020 Q4-2019 (actual)

Publication WMS 2020, Manuscript planned H1-2021 MDA 2020, Manuscript submission Jul-2020

92 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Zolgensma® - SMN1 gene replacement therapy

Study NCT03505099 SPR1NT (CL-304) NCT03837184 STRIVE Asia Pacific (CL-306) Indication Spinal muscular atrophy Type 1 spinal muscular atrophy

Phase Phase 3 Phase 3

Patients 30 6 • [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at Primary Outcome any visit Proportion of participants sitting without support Measures • [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit

Arms/Intervention Open-label, single-arm, single-dose, intravenous Open-label, single-arm, single-dose, intravenous

Pre-symptomatic patients with spinal muscular atrophy and Target Patients Patients with spinal muscular atrophy Type 1 multiple copies SMN2 Expected Completion H2-2021 H2-2021

Publication MDA 2020 (interim), Manuscript planned in H1-2021 TBD

93 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Zolgensma® - SMN1 gene replacement therapy

Study NCT03381729 STRONG (CL-102) Indication Type 2 spinal muscular atrophy Phase Phase 1

Patients 51

• Safety and tolerability, incidence of adverse events Primary Outcome • Proportion of patients achieving Standing Milestone Measures • Change in Hammersmith Functional Motor Scale

Arms/Intervention Open-label, single-arm, single-dose, intrathecal

Target Patients Patients with spinal muscular atrophy with 3 copies of SMN2

Expected Completion Q4-2019 [Cohort B] (actual); TBD [Cohort C]1

Publication MDA 2020, Manuscript planned for 2H 2020

1 FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study

94 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Oncology ABL001 – Specific, allosteric Bcr-Abl kinase inhibitor

Study NCT03106779 ASCEMBL (CABL001A2301)

Indication Chronic myeloid leukaemia (CML)

Phase Phase 3

Patients 233

Primary Outcome Major Molecular Response (MMR) rate at 24 weeks Measures

• ABL001 40 mg bid Arms/Intervention • Bosutinib 500 mg

Patients with chronic myelogenous leukemia in chronic Target Patients phase, previously treated with 2 or more tyrosine kinase inhibitors

Expected Completion Q3-2020 • Manuscript submission Q4-2020 Publication • Abstract submission to congress Q3-2020

96 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation ACZ885 – IL-1β inhibitor

Study NCT03447769 CANOPY-A (CACZ885T2301) NCT03631199 CANOPY-1 (CACZ885U2301)

Indication Adjuvant NSCLC 1st Line Non-small cell lung cancer (NSCLC)

Phase Phase 3 Phase 3

Patients 1,500 627 • Safety run-in part: Incidence of dose limiting toxicities Primary Outcome Disease free survival (primary), overall survival (key • Double-blind, randomized, placebo-controlled part: Measures secondary) Progression free survival (PFS) • Overall survival (OS) • Canakinumab or matching placebo in combination with • Canakinumab 200mg q3w sc for 18 cycles Arms/Intervention pembrolizumab and platinum-based doublet • Placebo q3w sc for 18 cycles chemotherapy Patients with: Patients with • High–risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB • Histologically confirmed Stage IIIB, IV NSCLC with no Target Patients (T>5cm N2)) after complete resection and standard of prior systemic anticancer therapy care adjuvant cisplatin-based chemotherapy • Squamous and non-squamous NSCLC • All histologies • No EGFR mutation and ALK rearrangement

Expected Completion Interim Analysis: 2022; Final: 2023 Interim Analysis: Q4-2020; Final: 2022 Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Publication TBD Manuscript submission Q4-2020 (safety run-in) Abstract submission to congress H1-2021 97 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation ACZ885 – IL1β inhibitor

Study NCT03626545 CANOPY-2 (CACZ885V2301)

Indication 2nd / 3rd Line Non-small cell lung cancer (NSCLC)

Phase Phase 3

Patients 240

• Safety run-in part: Incidence of dose limiting toxicities Primary Outcome • Double-blind, randomized, placebo-controlled part: Measures Overall Survival

• canakinumab in combination with docetaxel Arms/Intervention • canakinumab matching-placebo in combination with docetaxel

Patients with: • Stage IIIB or IV NSCLCwithout EGFR, ALK, ROS-1 or B- Target Patients RAF mutation • Previously treated with platinum therapy and PD(L)1- inhibitor

Expected Completion H1-2021

Publication Abstract submission to congress H1-2021

98 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation BYL719 - Alpha-specific PI3K inhibitor

Study NCT02437318 SOLAR-1 (CBYL719C2301) NCT04251533 EPIK-B3 (CBYL719H12301) Indication HR+/HER2- advanced breast cancer with PIK3CA mutation Triple negative breast cancer Phase Phase 3 Phase 3 Patients 572 566

Primary Outcome Progression-free survival (PFS) for patients with PIK3CA Progression-free Survival (PFS) for patients with PIK3CA Measures mutant status mutant status

• Fulvestrant 500 mg + alpelisib 300 mg • Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Arms/Intervention • Fulvestrant 500 mg + placebo • Placebo + nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with Men and postmenopausal women with hormone receptor either Phosphoinositide-3-kinase Catalytic Subunit Alpha Target Patients positive, HER2-negative advanced breast cancer which (PIK3CA) mutation or Phosphatase and Tensin Homolog progressed on or after aromatase inhibitor treatment Protein (PTEN) loss without PIK3CA mutation Expected Completion 2018 (actual) 2023 • Andre F, et al. Presentation at ESMO 2018 Publication • Andre et al. Manuscript N Engl J Med 2019;380:1929- TBD 1940.

99 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Exjade® - Iron chelation of bis-hydroxy-phenyl triazole type

Study NCT00940602 TELESTO (CICL670A2302)

Indication Iron overload

Phase Phase 2

Patients 224

To compare deferasirox to placebo with regard to event-free Primary Outcome survival in low and int-1 risk MDS patient with transfusional Measures iron overload

• Deferasirox, iron chelator Arms/Intervention • Placebo

Patients with myelodysplastic syndromes (low/int-1 risk) and Target Patients transfusional iron overload

Expected Completion 2018 (actual) • Angelucci E, et al. Presentation at ASH 2018 Publication • Angelucci E, et al. Manuscript Ann Intern Med 2020;172:513-522.

100 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation INC280 - MET Inhibitor

Study NCT02414139 (CINC280A2201) EGFR Wild-type, ALK negative advanced Non-small Cell Lung Indication Cancer (NSCLC) Phase Phase 2 Patients 364

Primary Outcome Overall Response Rate (ORR) Measures

• Pre-treated pts. with MET GCN: ≥ 6; ≥ 4 and < 6; < 4 • Pre-treated pts. with MET mutations regardless of cMET GCN as second or third line Arms/Intervention • Treatment-naïve pts. with MET dysregulation • Pre-treated pts with MET dysregulation – second line • Treatment-naïve pts with cMET mutations regardless of cMET GCN

Adult patients with EGFR wild-type (wt), ALK-negative advanced/ Target Patients metastatic NSCLC with either MET amplification or MET mutations

Expected Completion 2019 (actual) • Wolf J, et al. Presented at ASCO 2019 • Wolf J, et al. Presentation at ASCO 2020 (cohort 1 and 5a) Publication • Groen H, et al. Presentation at ASCO 2020 (cohort 6) • Wolf J, et al. Manuscript submitted Q1-2020

101 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Jakavi® - JAK1/2 inhibitor

Study NCT02913261 REACH2 (CINC424C2301) NCT03112603 REACH3 (CINC424D2301) Indication Steroid-refractory acute graft vs. host disease (SR aGVHD) Steroid-refractory chronic graft vs. host disease (SR cGVHD)

Phase Phase 3 Phase 3

Patients 310 330 Primary Outcome Overall Response Rate (ORR) at 28 Days Overall Response Rate (ORR) at 183 Days Measures

• Ruxolitinib 10mg bid • Ruxolitinib 10mg bid Arms/Intervention • Best available therapy (BAT) • Best available therapy (BAT)

Target Patients Patients with SR aGVHD Patients with SR cGVHD

Expected Completion 2019 (actual) Interim Analysis: 2019 (actual); Final: Q3-2020 • Zeiser R, et al. Manuscript N Engl J Med 2020;382:1800- 1810. • Manuscript submission in H2-2020 Publication • Zeiser R, et al. Abstract accepted for presentation at • Abstract submission to congress in H2-2020 EBMT Q3-2020

102 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Jakavi® - JAK1/2 inhibitor

Study NCT03491215 REACH4 (CINC424F12201) NCT03774082 REACH5 (CINC424G12201) Indication Acute graft versus host disease Chronic graft versus host disease

Phase Phase 2 Phase 2

Patients 45 42 Primary Outcome • Measurement of PK parameters • Overall Response Rate (ORR) Measures • Overall Response Rate (ORR)

• Ruxolitinib 5mg tablets / pediatric formulation Arms/Intervention • Ruxolitinib

Pediatric patients with grade II-IV acute graft vs. host disease Pediatric subjects with moderate and severe chronic Graft Target Patients after allogeneic hematopoietic stem cell transplantation vs. Host disease after allogeneic stem cell transplantation

Expected Completion 2023 2026

Publication TBD TBD

103 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Jakavi® - JAK1/2 inhibitor

Study NCT04097821 ADORE (CINC424H12201) Indication Myelofibrosis

Phase Phase 1/2

Patients 130 • Incidence of dose limiting toxicities within the first 2 Primary Outcome cycles Measures • Response rate at the end of cycle 6 • Ruxolitinib • Ruxolitinib+Siremadlin Arms/Intervention • Ruxolitinib+Crizanlizumab • Ruxolitinib+MBG453 Target Patients Patients with Myelofibrosis (MF)

Expected Completion 2024

Publication TBD

104 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Kisqali® - CDK 4/6 inhibitor

Study NCT03701334 NATALEE (CLEE011O12301C) Adjuvant treatment of hormone receptor (HR)-positive, Indication HER2-negative, early breast cancer (EBC) Phase Phase 3 Patients ~4,000

Invasive Disease-Free Survival for using STEEP criteria Primary Outcome (Standardized Definitions for Efficacy End Points in adjuvant Measures breast cancer trials)

• Ribociclib + endocrine therapy Arms/Intervention • Endocrine therapy

Pre and postmenopausal women and men with HR-positive, Target Patients HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy

Expected Completion Interim Analysis: H1-2022; Final: H2-2022 Publication TBD

105 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT03568461 ELARA (CCTL019E2202) NCT03876769 CASSIOPEIA (CCTL019G2201J) Indication Relapsed / refractory follicular lymphoma (FL) 1st line high risk acute lymphoblastic leukemia (ALL) Phase Phase 2 Phase 2 Patients 113 160

Primary Outcome Complete Response Rate (CRR) Disease Free Survival (DFS) Measures

Arms/Intervention Single-arm study of tisagenlecleucel Single-arm study of tisagenlecleucel

Target Patients Adult patients with relapsed or refractory FL Pediatric and young adult patients with 1st line high risk ALL

Expected Completion Interim Analysis: Q3-2020 2025 • ELARA interim analysis – ASH 2020, tbc • ELARA primary analysis – Planned for ASCO/EHA 2021 • ELARA vs RECORD full analysis – Planned for ASCO/EHA 2021 • High-risk patients (ELIANA/CASSIOPEIA) – Planned Publication • ELARA vs Flatiron – Planned for ASCO/EHA 2021 submission H1-2022 • ELARA: Primary analysis MS – simultaneous publication with congress • ELARA vs RECORD: Full analysis – simultaneous publication with congress

106 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Kymriah® – CAR-T therapy

Study NCT03570892 BELINDA (CCTL019H2301) Indication 2nd line Diffuse large B-cell lymphoma (DLBCL) Phase Phase 3 Patients 318

Primary Outcome Event-free Survival (EFS) Measures

Arms/Intervention Tisagenlecleucel versus standard of care Adult patients with aggressive B-cell Non-Hodgkin Target Patients Lymphoma after failure of rituximab and anthracycline- containing frontline immunochemotherapy Expected Completion H2-2021 • Westin et al. presentation at SOHO 2019, Bishop et al at SITC 2019, Bishop et al abstract planned to DGHO Publication 2020; BELINDA TiP • Primary analysis Planned for ASH 2021 • Primary manuscript – TBD

107 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation MBG453 – TIM-3 antagonist

Study NCT03946670 STIMULUS MDS-1 (CMBG453B12201) NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Indication Myelodysplastic syndrome Myelodysplastic syndrome Phase Phase 2 Phase 3 Patients 120 500

Primary Outcome Complete Remission (CR) rate and Progression Free Measures Survival (PFS) Overall survival

• Experimental: MBG453 + hypomethylating agents • MBG453 800 mg + azacitidine 75 mg/m2 Arms/Intervention • Placebo comparator: Placebo + hypomethylating agents • MBG453 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Adult subjects with intermediate, high or very high risk Target Patients Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Myelodysplastic Syndrome (MDS) as per IPSS-R criteria Chronic Myelomonocytic Leukemia-2 (CMML-2) Expected Completion H2-2021 2023

Publication Abstract submission to congress in H2-2021 TBD

108 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation PDR001 – PD-1 checkpoint inhibitor

Study NCT02967692 COMBI-i (CPDR001F2301)

Indication BRAFV600 mutant metastatic melanoma

Phase Phase 3 538 Patients Part 1 (safety-run in): 9; Part 2 (biomarker cohort): 27; Part 3 (Phase III, randomized, placebo controlled): 532

Primary Outcome Progression-Free Survival (PFS) Measures

• Spartalizumab 400mg i.v. Q4W + Tafinlar 150mg bid + Arms/Intervention Mekinist 2 mg • Placebo + Tafinlar 150 mg bid + Mekinist 2 mg Previously untreated patients with unresectable or Target Patients metastatic BRAF V600 mutant melanoma

Expected Completion Q3-2020 • Abstract submission to congress in Q3-2020 Publication • Manuscript submission Q3/Q4-2020

109 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation PDR001 - PD-1 checkpoint inhibitor

Study NCT03484923 (CPDR001J2201) Indication Previously treated unresectable or metastatic melanoma

Phase Phase 2

Patients 195

Primary Outcome Objective Response Rate (ORR) Measures

• PDR001 400mg i.v. Q4W + LAG525 (to be tested in unselected patients and LAG-3 positive patients) Arms/Intervention • PDR001 400mg i.v. Q4W + capmatinib • PDR001 400mg i.v. Q4W + canakinumab • PDR001 400mg i.v. Q4W + ribociclib

Adult patients with previously treated unresectable or Target Patients metastatic melanoma

Expected Completion H2-2021 Publication TBD

110 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Promacta®/Revolade® – Thrombopoetin receptor agonist

Study NCT03025698 (CETB115E2201) NCT03988608 (CETB115E2202) Previously untreated or relapsed/refractory severe aplastic Previously untreated or relapsed/refractory severe aplastic Indication anemia or recurrent aplastic anemia anemia or recurrent aplastic anemia Phase Phase 2 Phase 2 Patients 60 20

Primary Outcome PK of eltrombopag at steady state in pediatric patients with Hematologic response rate Measures SAA

• Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS • Arm B: previously untreated SAA-hATG/cyclosporine + eltrombopag Arms/Intervention • Eltrombopag 25 mg film-coated tablets • Arm A: relapsed/refractory SAA or AA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag

Pediatric patients from age 1 <18 years with Chinese patients with refractory or relapsed severe aplastic Target Patients relapsed/refractory SAA or recurrent AA after IST or anemia previously untreated SAA

Expected Completion 2025 2023

Publication TBD TBD

111 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Rydapt®- Multi-targeted kinase inhibitor

Study NCT03280030 (CPKC412A2220) NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia Acute myeloid leukemia Phase Phase 2 Phase 2 Patients 66 50

Primary Outcome Occurrence of dose limiting toxicities Incidence of safety events and event free survival Measures Event Free Survival ( EFS)

• Midostaurin 50 mg Arms/Intervention • Chemotherapy followed by Midostaurin • Placebo

Newly diagnosed patients with FLT3-mutated acute myeloid Newly diagnosed pediatric patients with FLT3 mutated acute Target Patients leukemia (AML) from pan-Asia countries myeloid leukemia (AML)

Expected Completion Interim analysis: Q2-2020 (actual); Final: H2-2021 2022

Publication Abstract submission to congress in Q4-2020 TBD

112 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03264989 SOLACE-Adults (CSEG101A2202) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Prevention of VOC in pediatric patients with SCD Sickle Cell Disease (SCD) Phase Phase 2 Phase 2

Patients 55 100

Primary Outcome PK/PD and safety of SEG101 (crizanlizumab) at 5 mg/kg PK/PD and safety of SEG101 at 5 mg/kg Measures

SEG101 (crizanlizumab) at a dose of 5.0 mg/kg (or 7.5 SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion Arms/Intervention mg/kg for exploratory group) by IV infusion, ± ± Hydroxyurea/Hydroxycarbamide Hydroxyurea/Hydroxycarbamide

Target Patients Adult SCD patients with VOC Pediatric SCD patients with VOC

H2-2021 (pediatric patients ≥6 year old) Expected Completion 2018 (actual) 2022 (pediatric patients 6 months – 6 year old) Publication Abstract submission to congress in Q3-2020 (7.5 mg group) Abstract submission to congress in Q3-2020

113 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation SEG101 – p-Selectin inhibitor

Study NCT03814746 STAND (CSEG101A2301) Prevention of Vaso-Occlusive Crises (VOC) in patients with Indication Sickle Cell Disease (SCD) Phase Phase 3

Patients 240

Primary Outcome Rate of VOC events leading to healthcare visit Measures

• Crizanlizumab 5.0 mg/kg Arms/Intervention • Crizanlizumab 7.5 mg/kg • Placebo

Target Patients Adolescent and adult SCD patients (12 years and older)

Expected Completion 2022

Publication TBD

114 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Tafinlar® - BRAF inhibitor

Study NCT01677741 (CDRB436A2102)

Indication BRAFV600 mutant cancers

Phase Phase 1/2

Patients 85

Primary Outcome Safety, tolerability and pharmacokinetics Measures

Single-arm study of oral dabrafenib (dose based on age Arms/Intervention and weight)

Pediatric subjects aged 1 year to <18 years with advanced Target Patients BRAF V600-mutation positive solid tumors

Expected Completion H1-2021 • Kieran MW et al. Manuscript Clin Cancer Res 2019;25(24):7294-7302 (PK analysis) Publication • Hargrave DR et al. Manuscript Clin Cancer Res 2019;25(24):7303-7311 (safety/efficacy in low-grade gliomas)

115 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Tafinlar®+Mekinist® - BRAF inhibitor and MEK inhibitor

Study NCT02684058 (CDRB436G2201) Indication BRAFV600 mutant gliomas

Phase Phase 2

Patients 142

Primary Outcome Objective response rate Measures

Arms/Intervention Dabrafenib + trametinib (dose based on age and weight)

Children and adolescent patients with BRAF V600 mutation Target Patients positive relapsed or refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade glioma (LGG) Expected Completion 2022

Publication TBD

116 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Tafinlar®+Mekinist® - BRAFV600 inhibitor and MEK inhibitor

Study NCT02124772 (CTMT212X2101)

Indication BRAFV600 mutant solid tumors

Phase Phase 1/2A

Patients 139

Primary Outcome Safety, tolerability and pharmacokinetics and clinical activity Measures

Trametinib (dose based on age and weight) Arms/Intervention Dabrafenib + trametinib (dose based on age and weight)

Pediatric Subjects Aged 1 Month to <18 Years with Target Patients Advanced V600-Mutation Positive Solid Tumors

Expected Completion H1-2021 • Geoerger B, et al. Presentation at ASCO 2020 Publication • Manuscript submission Q4-2020

117 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Zykadia® - ALK inhibitor

Study NCT02299505 ASCEND-8 (CLDK378A2112)

Indication ALK activated NSCLC

Phase Phase 2

Patients 306

Primary Outcome Part 1: Pharmacokinetics when taken with food Measures Part 2: Overall Response Rate (ORR) when taken with food

• Oral LDK378 450 mg once daily taken with food Arms/Intervention • Oral LDK378 600 mg once daily taken with food • Oral LDK378 750 mg once daily fasted

Adult patients with ALK-rearranged (ALK-positive) advanced non-small cell Target Patients lung cancer

Part 1 (PK): 2016 (actual) Expected Completion Part 2 (ORR): Q4-2018 (actual) Final (ORR): Q3-2020 • Part 1 (PK): Cho BC, et al. J Thorac Oncol. 2017 Sep; 12(9) 1357-1367 Publication • Part 2 (ORR): Cho B et al. J Thorac Oncol. 2019 Jul; 14(7) 1255-1265 • Final (ORR): Abstract submission to congress Q3-2020

118 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation 177Lu-PSMA-617 – Radioligand therapy targeting prostate specific membrane antigen (PSMA)

Study NCT03511664 VISION (PSMA-617-01) PSMA-positive Metastatic Castration-resistant Prostate Indication Cancer (mCRPC) Phase Phase 3

Patients 831

Primary Outcome • Radiographic Progression Free Survival Measures • Overall Survival

• 177Lu-PSMA-617 plus BS/BSC Arms/Intervention • BS/BSC alone

Adult patients with PSMA-positive Metastatic Castration- Target Patients resistant Prostate Cancer (mCRPC)

Expected Completion Q1-2021

Publication TBD

119 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Lutathera® - Radioligand therapy targeting somatostatin receptor type 2

Study NCT03972488 NETTER-2 (CAAA601A22301)

Indication Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Phase Phase 3

Patients 222

Primary Outcome • Progression Free Survival Measures

• Lutathera plus long-acting octreotide Arms/Intervention • high dose long-acting octreotide

Adult patients with Grade 2 and Grade 3 Advanced GEP- Target Patients NET

Expected Completion 2023

Publication TBD

120 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Ophthalmology Lucentis® - Anti-VEGF

Study NCT02375971 RAINBOW (CRFB002H2301) NCT02640664 RAINBOW Extension (CRFB002H2301E1) Indication Retinopathy of Prematurity (ROP) Retinopathy of Prematurity (ROP) Phase Phase 3 Phase 3 Patients 224 180

Absence of active Retinopathy of Prematurity (ROP) and unfavorable structural outcome at Week 24, defined as, 1) To evaluate the visual function of patients by assessing the Primary Outcome survival, 2) no intervention with a second modality for ROP, visual acuity in the better-seeing eye at the patient’s fifth Measures 3) absence of active ROP and 4) absence of unfavorable birthday. structural outcome

• Ranibizumab 0.2 mg (up to 3 injections max) • Ranibizumab 0.2 mg (up to Week 40, if warranted) Arms/Intervention • Ranibizumab 0.1 mg (up to 3 injections max) • Ranibizumab 0.1 mg (up to Week 40, if warranted) • Laser therapy

Male and female preterm infants with bilateral retinopathy of Male and female preterm infants with bilateral retinopathy of Target Patients prematurity (ROP) who require treatment. prematurity (ROP) who completed RAINBOW. Expected Completion 2018 (actual) 2023 • EURETINA: Sep-2018 • AAO: Oct-2018 • Primary manuscript published online by The Lancet in Sep-2019 (https://www.thelancet.com/pdfs/journals/lancet/PIIS0140 Submission of publication of 2 year data (Interim Analysis 2) Publication -6736(19)31344-3.pdf) in 2020 • Submission of manuscript on Pop PK/PD analysis in 2020 • Submission of manuscript on time-course of clinical response to treatment in 2020 122 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT02434328 HARRIER (CRTH258A2302) NCT02307682 HAWK (CRTH258A2301) Indication Neovascular age-related macular degeneration (nAMD) Neovascular age-related macular degeneration (nAMD)

Phase Phase 3 Phase 3

Patients 743 1,082

Primary Outcome Change in Best Corrected Visual Acuity (BCVA) from Change in Best Corrected Visual Acuity (BCVA) from Measures baseline at week 48 baseline at week 48

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Target Patients Subjects with exudative age-related macular degeneration Subjects with exudative age-related macular degeneration

Expected Completion 2018 (actual) 2018 (actual) • Year 1 Manuscript: Dugel P, et al. Ophthalmology 2019 Apr 12; HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. • Secondary publications planned for 2020 are: Fluid resolution, PCV and CNV subtypes, CST variability, the IPDA, safety Publication and VFQ outcomes submitting in Q1-Q3 of 2020 • Abstracts submissions on superior anatomic outcomes/Fluid/PostHoc results are planned for key retinal congresses (WOC; ARVO; ASRS, EURETINA AAO and APVRS) throughout 2020

123 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03386474 (CRTH258A2301E1) NCT03481634 KESTREL (CRTH258B2301) Indication Neovascular age-related macular degeneration (nAMD) Diabetic eye disease

Phase Phase 3 Phase 3

Patients 150 534

Primary Outcome Change from baseline in best-corrected visual acuity Number of treatment-emergent adverse events Measures (BCVA)

• Brolucizumab (RTH258) 3 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Brolucizumab (RTH258) 6 mg/50 µL • Aflibercept 2 mg/50 µL • Aflibercept 2mg/50 uL

Patients with neovascular age-related macular degeneration Patients with visual impairment due to diabetic macular Target Patients who have completed the CRTH258A2301 study edema (DME) Expected Completion 2018 (actual) H2-2021 Planned publication of the attributes of brolucizumab and Week 52 safety and efficacy data to be submitted as an Publication durability in Q1-2020 abstract in H1-2021 (KITE and KESTREL)

124 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03481660 KITE (CRTH258B2302) NCT04058067 KINGLET (CRTH258B2304) Indication Diabetic eye disease Diabetic macular edema

Phase Phase 3 Phase 3

Patients 356 268

Primary Outcome Change from baseline in best-corrected visual acuity Change in best-corrected visual acuity (BCVA) Measures (BCVA)

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Patients with visual impairment due to diabetic macular Chinese patients with visual impairment due to diabetic Target Patients edema (DME) macular edema Expected Completion H2-2021 2023 Week 52 safety and efficacy data to be submitted as an Publication Publication planned for 2023 abstract H1 2021 (KITE and KESTREL)

125 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03917472 KINGFISHER (CRTH258B2305) NCT03802630 RAPTOR (CRTH258C2301) Indication Diabetic macular edema Retinal vein occlusion

Phase Phase 3 Phase 3

Patients 500 500

Primary Outcome Change in best-corrected visual acuity (BCVA) from Change from baseline in best-corrected visual acuity Measures baseline up to week 52 (BCVA) at week 24

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Patients with visual impairment due to diabetic macular Adult patients with visual impairment due to macular edema Target Patients edema secondary to branch retinal vein occlusion Expected Completion H2-2021 2023

Publication Publication submission planned for 2022 Publication submission planned for 2023

126 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation RTH258 - Anti-VEGF

Study NCT03810313 RAVEN (CRTH258C2302) NCT04047472 HOBBY (CRTH258A2307) Indication Retinal vein occlusion Macular degeneration

Phase Phase 3 Phase 3

Patients 750 494

Primary Outcome Change from baseline in best-corrected visual acuity Change from baseline in best-corrected visual acuity Measures (BCVA) at week 24 (BCVA) at week 48

• Brolucizumab (RTH258) 6 mg/50 µL • Brolucizumab (RTH258) 6 mg/50 µL Arms/Intervention • Aflibercept 2 mg/50 µL • Aflibercept 2 mg/50 µL

Adult patients with visual impairment due to macular edema Chinese patients with neovascular age-related macular Target Patients secondary to central retinal vein occlusion degeneration Expected Completion 2023 2024

Publication TBD TBD

127 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation UNR844 - Disulfide bonds modulator

Study NCT03809611 (CUNR844A2203) Indication Presbyopia

Phase Phase 2

Patients 124

Primary Outcome Change in binocular distance-corrected near visual acuity Measures (DNCVA) from baseline at month 3

• 1.5% solution UNR844-Cl Arms/Intervention • Placebo

Target Patients Patients with presbyopia

Expected Completion Q1-2020 (actual)

Publication Expected at AAOptom

128 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Respiratory INC424 - JAK Inhibitor

Study NCT04362137 RUXCOVID (CINC424J12301) Indication COVID-19 (cytokine storm)

Phase Phase 3

Patients 402

Proportion of patients who die, develop respiratory failure Primary Outcome Measures (requires mechanical ventilation), or require intensive care unit care

• Ruxolitinib 5 mg tablet given bid Arms/Intervention • Placebo

Target Patients Patients with COVID-19 respiratory disease

Expected Completion (LPLV) Q4-2020

Publication Manuscript submission targeted for Q1-2 2021

130 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QBW251 - CFTR potentiator

Study NCT04072887 (CQBW251B2201) Indication Chronic obstructive pulmonary disease (COPD)

Phase Phase 2

Patients 956

Primary Outcome Trough FEV1 (Forced Expiratory Volume in 1 second) Measures change from baseline after 12 weeks of treatment • QBW251 450 mg • QBW251 300 mg • QBW251 150 mg Arms/Intervention • QBW251 75 mg • QBW251 25 mg • Placebo COPD patients on background triple inhaled therapy (LABA / Target Patients LAMA / ICS)

Expected Completion H2-2021

Publication TBD

131 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QMF149 - Long-acting beta2 agonist and inhaled corticosteroid

Study NCT02892019 (CQMF149G2202) Indication Asthma

Phase Phase 2

Patients 80

Primary Outcome Trough FEV1 Measures

• Indacaterol acetate 75 μg od (via Concept1 inhaler) Arms/Intervention • Indacaterol acetate 150 μg od (via Concept1 inhaler)

Target Patients Children ≥ 6 to < 12 years of age with asthma

Expected Completion 2019 (actual)

Publication TBD

132 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT02554786 PALLADIUM (CQVM149B2301) NCT02571777 IRIDIUM (CQVM149B2302) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 2,216 3,092 Primary Outcome Trough FEV1 Trough FEV1 Measures

• QMF149 150/160 µg od • QVM149 150/50/160 µg od • QMF149 150/320 µg od • QVM149 150/50/80 µg od Arms/Intervention • MF 400 µg od • QMF149 150/160 µg od • MF 400 µg bid • QMF149 150/320 µg od • Salmeterol 50 µg /fluticasone 500 µg bid • Salmeterol 50 µg /fluticasone 500 µg bid

Adult and adolescent (≥12 years) patients with asthma Adult (≥18 years) patients with asthma inadequately Target Patients inadequately controlled on medium/high-dose ICS or low- controlled on medium/high-dose of LABA/ICS (GINA step ≥4) dose LABA/ICS (GINA step ≥ 3) Expected Completion 2019 (actual) 2019 (actual) • Abstract: van Zyl-Smit et al, presented at BTS Dec-2019 Publication • Kerstjens H. et al. Lancet Resp Med 2020 (in press) • Van Zyl-Smit R. et al. Lancet Resp Med 2020 (in press)

133 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT03100500 (CQVM149B1305) NCT03100825 (CQVM149B1304) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 51 94 Long-term safety/tolerability: Incidence and severity of Long-term safety/tolerability: Incidence and severity of Primary Outcome treatment emergent adverse events during the 52 weeks treatment emergent adverse events during the 52 weeks Measures study study

Arms/Intervention • Single arm: QMF149 150/320 μg od • Single Arm: QVM149 150/50/160 μg od

Target Patients Japanese patients with asthma inadequately controlled Japanese patients with asthma inadequately controlled

Expected Completion 2019 (actual) 2019 (actual) • Japanese J Allergo (B1304/1305 combined); Planned in • Japanese J Allergo (B1304/1305 combined); Planned in Publication Q4 2020 Q4 2020 • Sagara H, et al. Abstract presented at ATS 2020 • Nakamura Y, et al. Abstract presented at ATS 2020

134 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation QVM149 - Long-acting beta2 agonist, Long-acting muscarinic antagonist and inhaled corticosteroid

Study NCT02892344 QUARTZ (CQVM149B2303) NCT03158311 ARGON (CQVM149B2306) Indication Asthma Asthma

Phase Phase 3 Phase 3

Patients 802 1,251 Primary Outcome Non-inferiority of Asthma Quality of Life Questionnaire Trough FEV1 Measures (AQLQ)

• QVM149 150/50/80 μg od • QMF149 150/80 µg od Arms/Intervention • QVM149 150/50/160 μg od • MF 200 µg od • Salmeterol/fluticasone 50/500 μg bid + tiotropium 5 μg od

Adult and adolescent (≥12 years) patients with mild asthma Target Patients inadequately controlled on low-dose ICS or low-dose Patients with uncontrolled asthma LABA/ICS (Gina step 2-3) Expected Completion 2019 (actual) 2019 (actual) • O. Kornmann et al. Respiratory Medicine 161 (2020) • Gessner C, et al. Respiratory Medicine (2020), doi: Publication • Abstract: D’Andrea et al, presented at ERS Sep-2019 https://doi.org/10.1016/j.rmed.2020.106021

135 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Xolair ® – anti-IgE antibody

Study NCT03369704 (CIGE025F1301)

Indication Seasonal allergic rhinitis: Severe Japanese Cedar Pollinosis

Phase Phase 3

Patients 337

Primary Outcome Measures Mean nasal symptom score, consists of severity of sneezing, rhinorrhea and nasal congestion.

In addition to standard of care: Arms/Intervention • Omalizumab per approved allergic asthma dosing table for IgE/body weight combinations • Placebo Patients with severe Japanese cedar pollinosis, whose symptoms were inadequately controlled with current recommended Target Patients therapies Expected Completion 2019 (actual) • Late breaking abstract was published at AAAAI (American Association of Allergy, Asthma and Immunology) annual meeting, Feb 2019 • Poster published at EAACI (the European Academy of Allergy and Clinical Immunology), Jun 2019 Publication • Oral presentations were made at JRS (Japanese Rhinologic Society), Oct 2019, and Asian Pacific Society of Respirology congress, Nov 2019 • Article published in “Allergy in Otolaryngology” (in Japanese), Jan 2020, and in “JACI: In Practice”, May 2020

136 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Sandoz Biopharmaceuticals Hyrimoz® - Biosimilar adalimumab

Study NCT02744755 ADMYRA (GP17-302) Indication Immunology Phase Phase 3 Patients 353 Change in DAS28-CRP score from baseline to week 12 in Primary Outcome patients treated with GP2017 and patients treated with Measures Humira®

• GP2017 Arms/Intervention • US licensed Humira® adalimumab

Target Patients Patients with moderate to severe active rheumatoid arthritis

Expected Completion 2018 (actual)

• Wiland, P. et al., presented at EULAR 2019 Publication • Wiland, P. et al., BioDrugs, Q2 2020

138 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation GP2411 - Biosimilar denosumab

Study NCT03974100 (CGP24112301) Indication Osteoporosis Phase Phase 3 Patients 522

Primary Outcome Percent change from baseline (%CfB) in lumbar spine Bone Measures Mineral Density

• GP2411 60 mg /mL subcutaneous injection every 6 months Arms/Intervention • Prolia® 60 mg /mL subcutaneous injection every 6 months

Target Patients Postmenopausal women with osteoporosis

Expected Completion 2022

Study data publications expected for 2024 and beyond. The Publication overall study design will be published at WCO and ECTS congresses 2020.

139 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Global Health KAF156 – Plasmodium Falciparum Inhibitor – PfCARL mediated

Study NCT03167242 (CKAF156A2202) Indication Malaria

Phase Phase 2

Patients ~500

Primary Outcome PCR-corrected adequate clinical and parasitological Measures response (ACPR)

• KAF156 and LUM-SDF (different combinations) Arms/Intervention • Coartem

Adults and children with uncomplicated Plasmodium Target Patients Falciparum Malaria

Expected Completion H2-2021

Publication TBD

141 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation KAE609 – Plasmodium Falciparum Inhibitor – spiroindolone against PfATP4

Study NCT03334747 (CKAE609A2202) Indication Malaria

Phase Phase 2

Patients 186 CTCAE grades increase from baseline in alanine Primary Outcome aminotransferase (ALT) or aspartate aminotransferase Measures (AST)

• KAE609 Arms/Intervention • Coartem

Target Patients Adults with uncomplicated Plasmodium Falciparum malaria

Expected Completion Q1-2020 (actual)

Publication TBD

142 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation Indication abbreviations

AD Atopic Dermatitis IPF Idiopathic pulmonary fibrosis AIH Autoimmune hepatitis mCRPC Metastatic castration-resistant prostate cancer aHUS atypical Hemolytic Uremic Syndrome MDR Multi-drug resistant ALL Acute lymphoblastic leukemia MDS Myelodysplastic syndrome ALS Amyotrophic lateral sclerosis MS Multiple sclerosis AMI Acute myocardial infarction nAMD Neovascular (wet) age-related macular degeneration AML Acute myeloid leukemia NASH Non-alcoholic steatohepatitis AS H2H Ankylosing spondylitis head-to-head study versus adalimumab nHCM Non-obstructive hypertrophic cardiomyopathy BC Breast cancer nr-axSpA Non-radiographic axial spondyloarthritis C3G C3 glomerulopathy NSCLC Non-small cell lung cancer CCF Congestive cardiac failure PDR Proliferative diabetic retinopathy CLL Chronic lymphocytic leukemia PEF Preserved ejection fraction CML Chronic myeloid leukemia PNH Paroxysmal nocturnal haemoglobinuria CRC Colorectal cancer PsA H2H Psoriatic arthritis head-to-head study versus adalimumab COPD Chronic obstructive pulmonary disease RCC Renal cell carcinoma COSP Chronic ocular surface pain PROS PIK3CA related overgrowth spectrum CSU Chronic spontaneous urticaria RA Rheumatoid arthritis CVRR-Lp(a) Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) rMS Relapsing multiple sclerosis CVRR-LDLC Secondary prevention of cardiovascular events in patients with elevated levels of LDLC ROP Retinopathy of prematurity DME Diabetic macular edema RP Retinitis pigmentosa DLBCL Diffuse large B-cell lymphoma refractory RVO Retinal vein occlusion GCA Giant cell arteritis SAA Severe aplastic anemia GVHD Graft-versus-host disease SjS Sjögren’s syndrome HCC Hepatocellular carcinoma SLE Systemic lupus erythematosus HFpEF Chronic heart failure with preserved ejection fraction SMA Type 1 Spinal muscular atrophy type 1 (IV formulation) HF-rEF Chronic heart failure with reduced ejection fraction SMA Type 2/3 Spinal muscular atrophy type 2/3 (IT formulation) HNSCC Head and neck squamous cell carcinoma SpA Spondyloarthritis HS Hidradenitis suppurativa SPMS Secondary progressive multiple sclerosis IgAN IgA nephropathy TNBC Triple negative breast cancer iMN Membranous nephropathy T1DM Type 1 Diabetes melitus

143 Novartis Q2 Results | July 21, 2020 | Novartis Investor Presentation